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POST AHSPHJEMAMIHB PURPURA.
SECTION I.
(A) A GENERAL CONSIDERATION OF PURPURA HAKMORRHAGIO A .
The term purpura is used to denote small haemor­
rhages into the skin, mucous membranes, and internal 
parts of the body. Purpura itself is not a disease, 
but rather a manifestation of one or more pathological 
influences at work within the body.
The outstanding feature of purpura haemorrhagica 
is bleeding from the mucous surfaces•
Certain blood investigations may assist in the 
elucidation of this particular type of purpura, such as
(1) The Thrombocyte count.
(2) Measurement of the bleeding time.
(3) The capillary resistance Test.
(4) Inspection of the blood clot for retraction.
Of these, the one which has given rise to most dis­
cussion is the first, which in cases of purpura fre­
quently shows the presence of thrombocytopenia.
The present position can be summarised by saying that, 
whatever their relative significance, both the plateletjs 
and the vessel wall are intimately concerned in 
purpuric haemorrhage.
2.
It is generally agreed that in the allergic sub­
ject, excessive sensitisation of the subject exists, 
i and from this it might be argued that excessive 
i  sensitisation of the capillary wall exists in some
people, and that purpura might be regarded as a purely I
j
allergic manifestation. |
But the direct cause of the damage to the endo­
thelium of the vessel wall in purpura haemorrhagioa 
is still a matter of doubt. A significant reference 
has been made by Kidd (1928) to the frequency of a 
focus of infection in a series of cases, in which he 
suggests the purpura was due to a streptococcal in­
fection, producing a mild toxaemia.
I Many observers adhere to the view that purpura
haemorrhagioa is a clinical entity, caused by a
diminution in the number of platelets. While it is
true that arsenical treatment does cause a temporary 
fall in the number of platelets (Hosahn and Pearce 
1934) there is not sufficient evidence to show that 
this is the primary cause of haemorrhage, or rather ,
I
there is much evidence to prove that a decrease in the!
i
number of platelets is not the essential cause of 
purpura following the administration of arsenobenzol 
compounds •
If the occurrence of haemorrhage is due to a fall
In/
3.
in the number of circulating platelets, then it follows 
that the cessation of haemorrhage should result in an 
increase in platelets*
!
| Discussing this point Hunter (1928) states that
|
•it has not been satisfactorily demonstrated that 
thrombopenia always precedes the purpura, or that a 
platelet rise is a precursor of the arrest of haemor-
ii
rhage•■ j
!
Foerster (Tidy 1928) describes a case where the ! 
cessation of haemorrhage actually preceded a rise in 
the number of platelets. Mackay (1931) states that 
in purpura haemorrhagioa the platelets are found in 
some cases diminished, and in others increased*
MacKay also found that in cases where toxaemia existed, 
a reduction in the number of platelets was a frequent 
occurrence, and that a spontaneous increase occurs, 
whenever the toxic factor is removed.
Platelets have been made to disappear from the 
circulation, by the injection of ante-platelet serum, 
without the event of haemorrhage occurring.
Tidy (1928) suggests that in considering the 
pathogenesis of purpura four structures fall to be 
considered 11) platelets (2) spleen (3) bone marrow
(4) endothelium*
With regard to platelets, it would appear from 
a mass of evidence that these bodies are diminished 
in/
4in some way when haemorrhage takes place, but as has 
been pointed out reduction in platelets prior to the 
onset of haemorrhage has never been proved, although 
a diminution in platelets appears to accompany the 
: haemorrhage.
If we admit that this reduction does take place, 
then two views fall to be considered: (1) that of
Kaznelson (1919) who thinks that there is a hyper- 
destruction of platelets due to overaction on the part 
of the spleen and 12) that of Frank (1925) who con­
siders it due to a fundamental defect in their pro­
duction in the bone marrow.
These theories are both based on the assumption 
that there does exist in purpura haemorrhagioa an 
actual reduction in the number of platelets, and that 
this reduction is responsible for the haemorrhage. 
However platelets can be absent from the circulation 
without the occurrence of haemorrhage and we must 
therefore look elsewhere for an explanation.
The spleen can only influence the haemorrhage 
through the platelets and as the same might be said of 
the bone marrow, we may take it that neither of these 
structures are implicated in the direct cause of 
haemorrhage.
With regard to the endothelium, increased permea­
bility or fragility is the only cause left for con­
sideration. It would seem that so long as the endo­
thelium is intact no haemorrhage can take place.
In/
In this connection the researches of Bedson (1922)
|
are important. He was able to demonstrate two factors | 
which give rise to haemorrhage, (1) injury to the 
I endothelium caused by injection of serum, and (2) re­
duction of platelets produced by injection of agar 
serum. It is a significant fact that neither of these 
alone produced haemorrhage. It would seem that if the 
endothelium remains intact no haemorrhage will occur 
even in the absence of platelets, but when the enio- ! 
thelium is damaged the deciding factor will be the 
number of platelets available for protection, and the 
maintenance of supply.
Several observers have noted a toxaemic factor 
present in their cases of purpura haemorrhagioa, and 
have attributed to this factor a possible cause for 
the onset of purpuric symptoms. This theory has not 
yet been very extensively studied and appears not to 
have impressed or interested any of the observers who j 
have studied cases of purpura haemorrhagioa following j 
the administration of arsenic. It is to add further 
evidence to this theory that this thesis is mainly 
concerned.
B . /
(B) CLASSIFICATION OF POST ABSPHENAMINE PURPURA.
In order to classify post arsphenamine purpura 
as a clinical entity a good deal of confusion has 
arisen in the attempt, and such classification as now 
exists presents a somewhat complex and confusing 
picture.
This is principally due to the fact that arsenical 
therapy has a depressing effect on the bone marrow 
which varies to a very great extent. Where a compara­
tively small amount of arsenic has been administered 
one may find evidence of a profound toxic action on 
the bone marrow, and where large doses of arsenic have
I
been given over a long period of years, the only evi­
dence of toxic effect may be a few purpuric spots with 
none of the other accepted signs of purpura haemorrhagioa 
present.
Various observers have endeavoured to establish a j 
new classification of purpura haemorrhagioa.
W.H. Kennedy (1928) suggests three groups:- j-
(1) Purpura without haemorrhage. j
(2) Purpura with haemorrhage. I
i
(3) Aplastic Anaemia with haemorrhagic
diathesis.
This observer states that in group (1) a purpuric !
eruption is present, but no haemorrhage from the 
sucous membrane takes place. He also states that in 
group/
group (2) there is a marked decrease in the number of 
platelets, and also a prolongation of the bleeding tim^ 
with non-retraction of the blood clot.
Dodd & Wilkinson (1928) have added another group - 
the agranulocytic cases. These authors review 24 
cases of this type of blood dyscrasia. It is of 
interest to note that in their own reported case, an
I
acute tonsillar infection was found to be present in 
the early stages of this complication.
Fairley (1930) believes that the type of Purpura 
Haemorrhagioa seen is dependent upon the degree of 
bone marrow depression. As arsenic does not always 
depress equally the elements of the haemopoietic system, 
it therefore follows that the clinical picture will 
vary in individual cases. In Fairley*s case - which 
was fatal at the 12th day - an ischio rectal abscess 
was discovered. Premonitory symptoms were well marked 
in this case.
Loveman (1932) states that where the arsphenamine I 
attacks only the platelets we get purpura, and depend­
ing upon the degree of intoxication we may have ueitheil 
simple purpura, purpura with haemorrhage, or if the !
bone marrow is involved purpura with aplastic anaemia, j
i
McCarthy and Wilson (1932) suggest that there are ! 
three main groups into which most cases can be placed.
(1) Thrombocytopenic group.
(2) The granulocytopenic group.
(3) The aplastic group.
8 .
"The characteristic feature of Group 1 is the
thrombocytopenia* Here there is usually very little
interference with the bone marrow function, and there |
I is no extreme degree of anaemia, unless of course j
I i
| haemorrhage is severe." It would appear as though ]
I
this group stands apart as a clinical entity and no j
explanation of this particular type of purpura has yet 
been advanced. But no hard and fast line can be drawn 
for there are other cases which although thrombocyto- j 
penia is a marked feature they show a certain degree !
: j
of granulocytopenia.
Groups 2 and 3 are closely related - both groups
; show depressed bone marrow function - the difference
i
! between the two depending on the extent to which the1
i
| white cell production has been involved.
Although the histological and pathological picture 
varies greatly in these groups, the clinical picture
is sometimes confusing. It i3 often impossible to make!
|
a diagnosis between the three groups without an examina­
tion of the blood film or a bone marrow puncture. !
Agranulocytosis and aplastic anaemia are already j 
definitely established diseases, and with these we are I
i
not directly concerned, except in so far that thrombo­
cytopenic purpura haemorrhage following the administra* 
tion of arsenic may closely simulate if not actually 
merge into the granulocytopenic and aplastic groups.
It may well be that post arsphenamine purpura is 
merely/
merely part of a more complex disease, and that the 
blood picture obtained in any given case depends upon 
the extent of damage done to the bone marrow. Even if 
that be so, the inclusion of such cases as McCarthy 
and Wilson* s groups 2 and 3 does not materially help to 
solve the phenomenon of purpura haemorrhagioa after 
arsenical treatment.
There is no doubt that following the administration 
Of arsenic all degrees of bone marrow damage can occur. 
In some cases there is no clinical evidence at all 
of purpura haemorrhagioa, and the only indication of 
some pathological process at work is the presence of 
gross damage to the bone marrow, such cases are natur­
ally labelled agranulocytosis or aplastic anaemia.
But again there may be all the clinical signs of 
purpura haemorrhagioa present, with very little evi- |
dence of bone marrow damage. !
Although haemorrhage into the skin and mucous 
membranes may occur with extreme bone marrow damage, 
one frequently finds that where haemorrhage is 
severe the bone marrow most frequently escapes. j
i
We know that toxins of whatever origin have a selective
affinity for different tissues, and the same toxin
acting at different times does not always attack the 
same tissue. It i3 therefore reasonable to argue 
that arsenic may at one time attack the endothelial 
lining/
lining of the blood vessels, at another time it may 
select the bone marrow, or at still another, affect 
both of these structures* It therefore follows that 
while haemorrhage in the form of purpura, may be 
the only sign of some pathological process at work in 
one patient, a blood picture indicating gross bone 
marrow damage may be the salient feature in another 
patient.
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SEOTIOH II.
THE DRUG *
After many years of search for an
efficient spirochaeticidal agent which could be used 
clinically Ehrlich and his co-workers discovered 
"arsphenamine" in 1901. As it was the 606th product 
in the series being investigated it soon became known 
as 606 and the patent name given to it of salvarsan. 
The term arsphenamine came into use during the World 
War 1914-18 when the drug was manufactured in the 
U.S.A. Synonyms for it include arsenobenzol and 
diarsenol. The administration of salvarsan was 
associated with many technical difficulties so that 
Ehrlich continued his researches to discover neo- 
salvarsan as the result of his 914th test. Present 
day synonyms for this are novoarsenobenzol, neo- 
arsphenamine (U.S.P. and B.P.) Proprietary manu­
facturing chemical firms have added their own dis­
tinguishing labels e.g.
Hovoarsenobillon is neoarsphenamine made by May & Baker
Heokharsivan * " * " Burroughs
Wellcome and Co.
Stabilarsan/
Stabilarsan is an arsphenamine compound made by Boots j
in which arsphenamine is combined with glucose, but in j
|
dosage and action is equivalent to a neoarsphenamine 
derivative. Neoarsphenamine is sodium 3.3 diamine 
4 4 dihydroxyarsenobenxene methanal sulpoxylate.
Its formula is represented by
\]nH,CHx0.30^.
OH. OH
It contains 19-22 per cent of arsenic in the trivalent 
form and is a canary yellow powder dispensed in vacuum 
or nitrogen filled glass ampoules. The standard dose 
for a 12 stone man is 0.6 gm. given intravenously dis­
solved in 10 cc. of sterile water once weekly. Dose 
for a woman is from 0.15 to 0.45 gm. once weekly.
Sulpharsphenamine was developed in 1922 in the 
Hygienic Laboratory of the United States Public Health
Service and has the chemical formula
a -  a  »KOS H A/ II I lASU.C#t0. $0/Vu4
both amino groups being closed. It is also a light
yellow powder 19 per cent of trivalent arsenic but is 
relatively more soluble than any of the other members <jf 
"914* group and is suitable for intramuscular adminis­
tration in a dose of 0.15 to 0.45 gms. dissolved in 1-3 
cc. of sterile water, given once per week. |
Prom a clinical point of view the action, both 
therapeutic and toxic, of all the above drugs is so 
similar that it is convenient to use the name 
"arsphenamine" as a comprehensive adjective e.g. post- 
arsphenamine/
post-arsphenamine purpura, and not necessarily specify­
ing which particular brand of drug was used.
TOXICOLOGY.
In reviewing the literature on the toxicological
I
aspects of the arsphenamines three factors at once i 
emerge, namely, the arsenical content of the drug, the 
benzene component in the drug and the influence of
i
allergy. Each of those or any combination of them 1 
.may play a part in the production of post-arsphenamine ,
purpura. |
|
When it is considered that the maximum adult dose 1j
! of *914" or its equivalent, introduces into the body I
:  '  i
! an amount of arsenic approaching twenty-five times the !
i  •  !
fatal dose, of inorganic arsenic, it is not t‘o be j
woniered at that toxic effects are common. j
Stokes (1934) states that the trivalent arsenical^ 
have a special affinity for vascular structures such a^ 
the. small arterioles and capillaries below the skin 
papillae• j
Anwyl-Davies (1921) believes that the purpura is 
caused by damage to the capillary endothelium by the 
arsenic contained in the arsphenamine• |
Osborne quoted by Stokes suggests that a large ; 
part of the injury produced by the trivalent arsenicals 
is associated with damage to the capillaries in whose 
walls extensive deposits of arsenic can be demonstrated. 
FIandin/
14.
Plandin and Tzanck (1922) believe that arsphenaminje 
disturbs the normal coagulation of the blood* They
1 report that the coagulation of the blood may be pro-
j
!longed to thirty minutes and upwards following the 
injection of arsphenamine. They go so far as to sugges 
that arsphenamine is superior to citrate as an ante- 
coagulant of the blood. These authors believe that 
arsphenamine acts upon the thrombin or its precursors 
and not upon the blood elements.
McCarthy and Wilson (1932) state that the ars- 
phenamines appear to have at least two separate action^
i
- one a depression of the bone marrow and the other a j 
toxic action on the platelets. The question as to j 
whether any one particular type of arsphenamine•is more
ii
likely to cause purpura has not been solved. |
Moore and Foley (1920) state that the most satis- j 
factory theory is that there is some impurity in the |
i
drug which causes the purpura, or alternatively that urjder
certain circumstances in the body, during the course of!
!
the metabolism of the drug, a substance is formed .whicii
if
leads to the development of purpura. j
It is equally a matter for thought that the benzol
i
radical is responsible for the development of purpura
i
as all the arsenicals used in treatment contain the i 
benzol radical, and there can be no doubt that purpuric 
symptoms do occur as a result of benzene poisoning. 
Hikulina and Titowa (1934) find thrombocytopenia very
frequently among benzol workers (seventy-three out of 
seventy-six cases).
16#
Selling and Osgood (1935) state that in chronic Benzdne 
Poisoning, anaemia is an outstanding symptom. Petechial 
haemorrhages may occur, also nose bleeding or excessive 
menstrual period.
Eohner, Baldridge and Hansmann (1926) in an article on ! 
Chronic Benzene Poisoning instance the case of a male
i
patient, with bleeding from the gums and rectum, and j
i
haemorrhages into the skin. In thi3 case the haemoglobin 
was 20$. White cells 1,400. Platelets 70,000. 
Observations carried out by Falconer and Epstein (1936) 
suggest that an allergic phenomenon i3 responsible for j
the complication, rather than some oxidation product, j
j
formed by the breaking down of neoarsphenamine in the Il
i
body, as was first thought. j
The accepted view seems to be that the fundamental 
basis for symptoms is the destructive action of the 
benzol radical on the haematopoietic tissues. If this !
were the only factor involved, it is not clear why onljj
!
certain individuals develop purpuric symptoms. In vievij 
of the almost universal use of arsenic in the treatmenlj 
of syphilis, one would reasonably expect this com- ! 
plication to be much more prevalent than it actually j
i
is, if only the arsenic was at fault. The incidence 
of purpura haemorrhagioa is much too low for the benzol 
radical per se to be the only factor in the aetiology. 1 
Idiosyncrasy, or sensitisation, or some toxic factor 
may play a part.
SECTION III.
STUDY OF CASES REPORTED IN LITERATURE.
When one considers the almost universal use of 
arsenobenzol and its derivatives in the treatment of 
syphilis, it is very surprising that so few cases of
purpura haemorrhagioa have so far come to light. j
i
Labbe and Langlois were the first to draw attention to j
|
this serious complication of arsenical therapy in 1919.;
i
It is hardly conceivable that such a very unusual ! 
complication could occur and pass unnoticed, or when 
observed should have passed without comment. Even if
|
cases were overlooked by the medical staffs of hospitals 
and clinics, the symptoms of the complications are so 
unusual and come on with such suddenness, it is not j 
likely that the patient would allow such symptoms to 
pass without remark. Therefore one i3 inclined to j
accept such cases as have been published, as approxi- i
!
mately representing the true number which have occurred•
j
No attempt has been made to review here every case of j
i
arsenical purpura which has been published• But a |
j
sufficient number of cases have been examined in order j 
to reach some definite conclusion regarding the 
phenomenon.
Purpura may be regarded as a rare but serious
complication in the administration of arsenic.
(193 i)
Cole and his co-workers- observed only two cases
out/
17#
out of a total of 338 complication*, their cases in­
cluding over 78,350 injections of various arsenicals 
in 1,212 patients over a ten year period.
The Salvarsan Committee (1922) make no mention of 
purpura haemorrhagioa as a complication of arsenical 
treatment in syphilis.
More recently Burke (1941) states that over a 
period of eight years 2,838 cases of syphilis were 
handled at the Salford Municipal Clinic, and no case 
of thrombocytopenia or indeed any state of Blood 
Dyscrasia occurred.
Again, at the Vi/hitechapel Clinic during a four 
year period, 3,250 syphilitic patients were treated 
and there were only thirteen cases of Blood Dyscrasia, 
ten of these patients were cases of thrombocytopenia.
Bickford and Tilghman (1933) in reporting two 
cases of purpura haemorrhagioa occurring in children 
with congenital syphilis state that their records show 
that out of 1,825 children treated over a period of 
eleven years, involving 25,950 treatments, only two 
cases of purpura haemorrhagioa occurred, nearly every 
child was treated with neoarsphenamine•
Falconer, Epstein and Wever (1936) find only four 
cases of purpura haemorrhagioa reported from the 
Syphilis Clinic at the University of California, where 
60,000 treatments have been administered 3ince 1924.
The/
TABLE X .
Case 
Nos • Sex Age Drug
too.
of
Inject.
Pro­
dromal 
Symp­
toms •
inter­
val. Hae • Hb
1 P - Neo-
arsphen
16 + Not
stated
++ -
2 P 50 M 10 • + 6 hrs. 64
3 P 23 Novarseno-
billon
8 - 12 hrs. Nil -
4 P 51 Unknown 5 + 4 hrs. + - -
5. M 37 Sulph- 
arsenol•
13 m 1 hr.
6. M 44 Neo-
arsphen.
24 + Immed. -
7. M 54 Arsphenamine
Sulpbar-
sphenamine
15 “ 21 days 40
8. F 26 Neoars-
phenamine
17 +• 1 hr. ++ m
9. M 30 N.A.B. - - 24 hrs. + 80
10. F 51 Neoarsphen. 30 - 11 days + -
11. F 28 Sulphostab. 25 Nil 10 hrs • ++ -
12. P 29 M .A .B . 10 + 7 days ++ 55
13. P 38 Sulphostab. 18 + 5 days + 86
14* M 55 M.A.B. 10 m 12 days 38
15. M 49 Neoarsphen. 21 3 hrs. + 75
16. M 29 Neoarsphen. 23 1 hr. -
17. M 6 Neoarsphen. ( 70 ) 
{approx)
24 hrs. + 86
18. M 8 Neoarsphen. 13 + 1 hr. + 80
19. M 33 Neoarsphen. 16 + Pew days + 46
20. M 48 Neoarsphen.
Bismarsen
46 + 11 hrs. ++ -
$6 cases reviewed.
Lympho- “ — — — — .
Beds Whites Polys, cytes Monos. Baso. Eosin. Plate- Hesult 
% % % % % % f lets •
1,601,000 4650 30 £5 35 Died
3,176,000 1100 11 84 5 Mil Died 
Bee.
Bee.
Died
Bee.
2,810,000 1900 16 80 0.4 - 175,000 Died
60,000 Bee.
3.200.000 1500
3.400.000 3,000
2.630.000
5.760.000
1.810.000
4.500.000
4.500.000
4.700.000
4.290.000
2.330.000 
Normal
2,500
5.800 
Lympho s
only
(1700)
7.000
6,200
7.800
7.000 
4500
N ormal
18
4
2
62
Mil
67
44
67
76
35
88
92
25
1700
27
31
14
47 Mil Nil 10,000 Died
- 50,000 Bee.
- 150,000 Bee.
2 4 - 180,000 Died
11 1 1 42,000 Bee.
Mil - Mil Died
1 - 5  Low Bee.
• Low Bee.
- ' - - Low Bee •
• Mil Bee.
• - 6 Mil Ree.
• Normal Bee.
TABLE I .
Case
N os. Sex Age Drug
T T o T ---Pro-
of dromal
Inject. Symp­
toms •
Inter- 
val. Hae. Hb.jC
12
24
unknown
6
7
21. M 40 Sulph-
arsphen
22. M 34 Beoarsphen.
23. P 48 Beoarsphen.
24. M 37 Beoarsphen.
25. M 30 Beo-
kharsivan
26. M 30 Beoarseno- 14
benzene &
Sulphar-
senobenzene
27. M 53 Neoarsphen. 16
sulpharsph.
28. M 58 Sulpharsph. 50
Stabllarsan
29. M 41 Beoarsphen. 25
30. M 52 Neoarsphen. 12
Sulpharsph.
3 1 . M 14 Sulpharsph. 48
Stabilarspn
32. P 21 Sulpharsph. SO
33. F 26 Neoarsphen. 35
Sulpharsph.
34. P 24 Neoarsphen. 38
Sulpharsph •
35. F 31 Sulpharsph. 10
36. F 51 Neoarsphen. 27
Sulpharsph.
Not
stated
Nil
4 hrs •
1 hr. 
Few
minutes 
3 hrs • 
18 hrs.
5 days
+
+
42
72
85
90
50
102
4 days 
58 days
1 day
2 days
7 days
I day +
6 days +
1 day +
3 days + 
Few days +■
Purpuric
spots
Purpuric 82 
spots
Purpuric
spots
Purpuric 98 
rash
Purpuric 94 
spots
80
28
70
continued.
Red s 
%
Whites
%
O 
!
v* (0 •
Lympho­
cytes
%
K o
's
ap o . Baso.
%
Eosin Plate- 
% lets
Result
3,000,000 24,000 87 10 2 - 1 Nil Reo •
3,870,000 11,600 63 18 13 - 5 30,000 Rec •
4,410,000 5,150 67 16 13 Ml 3 10,000 Rec.
4,600,000 8,360 76 8 12 - 4 80,000 Reo •
2,620,000 4,400 60 26 13 m - Nil Rec.
5,180,000 - - - • - m 30,000 Reo •
- - - m m - m Reo.
5,300,000 9,200 78 20 - - 1 50,000 Reo.
| m - - - - m m Reo.
6,200,000 7,200 67 32 - m 1 120,000 Rec.
4,900,000 5,000 50.5 39.5 - m 2.5 264,800 Reo •
4,900,000 10,400 60 34 - - 2 Very few Rec •
- m - - m - - - Rec.
|
- - - oft m m - Rec •
1.940,000 6,000 70 27 m m 1 5,000 Rec •
5,100,000 5,600 58.5 31 - - 4 193,000 Rec •
|
+ 4 
+ 
ii 
u moderate Haemorrhage, 
severe Haemorrhage•
Authors Reporting Cases Reviewed in Table I,
Case
No* Authors • Date •
1* Labbe & Langlois (1919)
2. Moore & Keidel (1921)
3. T. Anwyl-Davies (1921)
4. FI or and, Mcaud & Froment (1922)
5. T.P. Buist (1925)
6. C. Morton Smith (1926)
7. F.C. Combes (1927)
8* W.R. Kennedy ^1928)
9* M.M. Bocage and Le Filliol (1929)
10. B. Appel (1930)
11-14 Bamforth <Sc Elkington (1931)
15-L0 McCarthy & Wilson (1932)
17-18 Bickford & Tilghman (1933)
19. A.B • Loveman (1932)
20. J.Ju. Griand (1934)
21. E.H. Hudson (1935)
22-24 Falconer, Epstein & Wever (1936)
25. D.R. Gorrie (1940)
26. S.M. Laird (1942)
27-36 E.T. Burke (1942)
18
The foregoing table gives the blood findings in j 
the oases reviewed• In nine instances however* no j 
blood examination was carried out. In some other 
cases a blood examination was done each day for several 
days after the onset of purpuric symptoms. The result 
of blood examination carried out immediately following 
the onset of symptoms has been tabulated. In the 
following table Prodromal symptoms will be taken to '
i
indicate such reactions as the following: rash* mal- 1
!
aise, nausea* headache* petechiae or bleeding into 
the skin or mucous membrane* bleeding from nose and ^
gums* and vagina* nitritoid reaction* haematuria* |
mel^na* chilly sensation* vertigo.
I
j
Conclusions to be drawn from a study of the foregoing
!
table:- j
(1) Sex. j
It will be seen that out of thirty-six cases !
ji
reviewed twenty-one of these are males. There is veryj
i
little evidence however to suggest that the complica- jj
tion occurs more frequently in any one sex. Seven j
I
cases died out of the total number, four of the seven ;
deaths occurred in females. I
(2) Age. !
Mo special significance can be attached to j
the age factor. The common age group would appear to 
be between twenty years and fifty-five years.
The type of arsenical used in the foregoing thirty- 
six cases is given in Table II.
Neoarsphenamine was the drug most frequently ad­
ministered. Next in order comes Neoarsphenamine oom- 
bined with Sulpharsphenamine, then sulpharsphenamine 
alone.
TABLE II.
Drug. No. of cases 
in which used.
%
N e oars phenamine 19 54.3
Neoarsphenamine + 
Sulphars phenamine 6 17.0
Neoarsphenamine + 
Bismarsen 1 2.9
S ulphars phenamine 4 11.5
Sulpharsphenamine + 
Stabilarsin 2 5.7
Sulpharsphenamine + 
Arsphenamine 1 2.9
Sulphostab 2 6.7
It will be noted that Neoarsphenamine was used 
alone in 19 cases out of 35, Neoarsphenamine + Sulph­
arsphenamine was used in six cases out of 35, and 
Sulpharsphenamine alone in four cases• In one case th^ 
drug used was unknown. Neoarsphenamine or Sulphars­
phenamine was therefore used in 82.8 per cent of the 
cases reviewed.
Whilst/
2 0 .
Whilst therefore neoarsphenamine appears .to be
| the drug which most frequently gives rise to purpuric
j
| symptoms, this is probably because of its more general
!i
I use, and had sulpharsphenamine been used to the same
i
extent no doubt this latter drug would have given rise j 
; to a greater proportion of reactions.
(3) Humber of Injections.
The average number of injections administered 
in each case amounts to about twenty.
It will be noted from Table I that in no case had 
the patient received less than five injections of j
arsenic before the onset of symptoms. On the other 
hand, one patient, a child aged six, received no fewer 
than seventy injections before the onset of purpura.
i
In one case reported by Emile-Weil and Isch-Wall (1927)1
I j
purpuric symptoms occurred after only two injections, j 
This would seem to nullify the view held by some j
observers, that the arsenic has a cumulative effect |
ii
or that a certain time must necessarily elapse before 
the drug exerts its toxic influence. j
In view of the great variation in the number of doses j
; i
given, it would appear that this is not a factor which |
: i
influences the onset of post arsphenamine purpura. J
However it may be stated that, as a general rule, j
j
purpura following the administration of arsenic usually 
occurs after several doses of the drug has been given.
( 5 ) /
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i
i
\ 1(4) Prodromal Symptoms.
In many oases after the advent of symptoms
i further doses of the drug were given. In twenty-two
; I
cases out of a total of thirty-six (61 per cent) pro- !
i
dromal symptoms of one kind or another were present.
The percentage might even be higher as in a few instancies 
no record is available as to whether prodromal symptoms 
were present or not. It is certain that had sufficient
. I
care been exercised in questioning the patients as to
I
previous sensations after arsenical injections, some j
of these cases of purpura haemorrhagica could have
i
been avoided. It would appear that once any untoward j 
reaction occurs which might suggest an intolerance to 
arsenic on the part of the patient, the reaction should
be regarded as a stern warning that no further arsen- j
!
ical preparations should be administered - not even j
;  i
after a lapse of years. A period of rest from arsenicajl
I j
: treatment does not appear to bestow immunity or give
further protection against any further reaction. j
: • | 
Various authors have commented upon this question |
I of apparent sensitivity on the part of the patient. j
Bickford and Tilghman report the case of a child
aged six, in whom purpuric symptoms recurred after only
the second injection of arsenic, the child having had
no arsenic in a two year interval.
Falconer, Epstein and Wever report the case of a
male/
; male patient, aged 34, who received twenty-four in- 
; jections of neoarsphenamine• Ko further arsenic was 
administered for thirteen months. On the recommence­
ment of treatment, the fourth injection of neoarsphen­
amine was followed by a severe reaction with purpuric 
symptoms. In this case a year did not suffice to j
abolish the sensitivity to arsenic. j
i
j
The chief points illustrated by these cases are: I
(1) that neither the individual dose of the drug nor 
the number of doses administered over a prescribed
i
; period of time, has any direct bearing on the causej
of the complication. j
(2) that the sensitivity is not dependent upon the J
amount of the drug previously administered. !
(3) that post arsphenamine purpura haemorrhagica is a 
complication which generally occurs only after 
repeated injections. j
' I
U )  that the patient appears to become in some way j
unduly sensitive to the arsenic.
;
(6) Interval between injection and onset of symptoms j 
Purpura haemorrhagica is an acute complication 
I which appears with great suddenness. In the cases 
| collected from the literature the average time elapsing;
I
i between the last injection and the occurrence of pur­
puric/
purpuric symptoms is about four days, the shortest
i
period being apparently a few seconds, and the longest j
j
being fifty-eight days. In one case, (the first of j
!
the series) no time is stated, in two cases, a few j 
days is the time given. In not a few cases, the j
I
patients left hospital after their arsenical injection I 
feeling well, only to return a few hours or days later | 
with well marked clinical signs of purpura. i
i
(6) Haemorrhage. |
j
The extent and the degree of the haemorrhage j
varies. Most frequently it takes the form of spont- j
i
aneous extravasation of blood into the skin, petechial ;
ii
spots, nose bleeding, and bleeding from the gums. j
Haemorrhage from the vagina, rectum and bladder appears 
to be less common. The amount of haemorrhage appears ! 
to depend upon the degree of thrombocytopenia present, ! 
but there are certain exceptions to this generalisation.
The following table shows that the relationship 
between the haemorrhage and the number of circulating 
blood platelets is not always a constant factor.
TABLE III./
TABLE III.
Case Ho.
Degree of 
haemorrhage•
Platelet 
0 ount• ii
2 Moderate Nil
!
i
7 Severe 175,000
i
12 Severe 18,000
18 Moderate M l
19 Moderate Nil !
1
It would seem, therefore, that apart from any effect i
i
caused by a diminution in the number of platelets, somej 
other factor may play a part in the degree of haemor- j
i
rhage, such as, the extent of damage to the endotheliunj 
of the vessel wall, or some interference with the normal 
blood coagulation complex. |
; I
In the literature reviewed, references to post- j 
mortem findings are very scanty, and details as to the j
ii
extent and severity of the haemorrhage have been seldomj 
recorded.
ii
Buist (1925) found post-mortem, haemorrhage into j
s
the skin, lips, wall of the left ventricle, mesenteriesj, 
great omentum and large intestine, with bleeding into 
both kidneys, and petechial haemorrhages at the base of 
the brain.
Bocage and Le Filliol (1929) found post-mortem a
ii
large haemorrhage into the intestine, and purpuric spotp 
over the surfaces of the heart, with larger haemorrhagio 
areas/
25
areas near the orifice of the tricuspid valve* i
Haemorrhage therefore is not confined to any particular 
region but may be present in any organ or take place 
from any part of the mucous membrane•
(?) Haematological Findings.
(1) Haemoglobin and Differential Blood cell count*
The Hb. percentage is given in twenty-two 
out of the thirty-six cases reported upon.
In eight of these twenty-two cases the Hb. percentage 
was found to be under 65.
In one case (the first of the series) the percentage 
of haemoglobin was not actually recorded, but as the 
red cell count was found to be below two million it 
may be taken for granted that the Hb. percentage was 
below 65.
It follows that only about 40 per cent of the.recorded 
cases show a marked degree of anaemia.
A slight degree of anaemia is present in only 13.5 
per cent of cases.
A marked diminution in the number of red cells is 
present in these cases which proved fatal, the average 
red cell count being 2,537,000 per c.cm. as compared 
with 4,230,000 per c.cm. in those cases which recovered.
(2) A study of the white cell content of the blood was 
made in 25 cases.
Leucopenia was present in 9 cases. |
Of/
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Of these nine cases, three recovered, and six died.
In those cases which recovered, in one instance the 
blood showed the presence of a monocytosis, and in 
another a granulocytopenia.
The average white cell count in these three cases was
j
3966 cells per c.mm, and the percentage of polymorpho­
nuclear cells was 47.
Of the six cases which died, five showed agranulocyto- I 
penia, accompanied by a lymphocytosis in four instances. 
The sixth case showed an absolute agranulocytosis and 
a lymphocytosis.
The average white cell count in these six cases was 
2225 cells per c.mm., with an average of 15 per cent 
polymorphonuclear cells.
The conclusions to be drawn from the data obtained 
from these blood examinations may be summarised as 
follows:-
(1) A severe degree of secondary anaemia is not always 
present in cases of post arsphenamine purpura.
i
Anaemia to some extent is present in about 50 per 
cent of cases.
(2) The presence of granulocytopenia is a grave omen, 
and the prognosis would appear to depend upon the
I
degree of granulocytopenia present. j
i
(3) In many cases of post-arsphenamine purpura, the I
i
bone marrow escapes damage, and in these cases the; 
prognosis is on the whole good. j
(4)/
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(4) Examination of the blood is essential from the 
prognostic point of view, and this should be 
carried out immediately any sign of purpura is 
apparent.
(8) The Platelets
It is still a matter of doubt as to the actual 
part played by the blood platelets in purpura haemor­
rhagica, and although thrombocytopenia f r e q u e n t l y  
accompanies purpura haemorrhagica some writers do not 
admit that this is of any clinical or pathological 
significance. It would appear that under normal con­
ditions of health, the numerical range of the platelet
(1951)
count varies to a considerable extent. MacKay states
that the normal numerical limit may be anything betweerf
|
250.000 and 450,000. j 
Dameshek (1932) gives the normal limit as between
500.000 and 900,000. As we are mainly concerned with 
the significance of a low blood platelet count, any 
figure below 250,000 per c.cm. will be taken to indicatfe 
that thrombocytopenia exists.
Most observers agree that there is a decrease in 
the platelet count in post arsphenamine purpura.
From a study of the cases examined this view appears 
to be correct.
It/
It will be noted that an examination of the blood j 
platelets was made in twenty-seven patients out of the | 
total number of thirty-six. j
In two oases the number of blood platelets was j
i
stated to be "normal".
In one case "very few" were observed and in three 
cases the platelet count was "low". In fifteen cases
i
the blood platelets were decreased, and in six cases j 
absent altogether. Thrombocytopenia was therefore j
present in twenty-five out of the twenty-seven cases, j
i
that is in 92.5 per cent of oases. j
Actual figures of the platelet count are given 
in twenty-two cases, and the average count works out at 
65,445 platelets per c.mm. per patient. j
Five deaths occurred in cases showing thrombocytopenia. 
Of these, only two patients showed complete absence of ; 
platelets. The average platelet count in the other j
i
three cases was 121,000 platelets per c.mm.
In the patients who survived the complication, the 
average platelet count was 63,223 per c.mm. per patienti.
From these figures one might conclude that whilst j 
the thrombocytopenia almost invariably accompanies posi 
arsphenamine purpura the number of platelets in the 
circulating blood does not appear to have a direct 
bearing upon the prognosis of this complication.
Zunz/
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Zunz and Vesselovsky (1934) in their experiments 
on the rabbit noted a diminution in the number of 
platelets in the carotid blood five to ten minutes 
after the intravenous injection of 0.1 to 0.2 gm. 
neoarsphenamine or sulpharsphenamine. '
Jui-Wu-Mu (1929) states that the platelets show at! 
first a fall in from ten to thirty minutes and then a
!
rapid rise, after the intravenous injection of neo- j
I
arsphenamine. In a study of fourteen cases he found j
i
a fall in the number of platelets in ten cases, the |
j
platelets then numbering 170,000 to 300,000 per c.cm.
i
and no patient developed purpura haemorrhagica. The j 
platelet count was normal six hours later. j
W.K. Kennedy (1928) states that it is a common | 
observation that haemorrhagic lesions develop where !
j
the blood platelet count is below 60,000. This author j
I
states that haemorrhage occurs when the toxic influence' 
of the arsenic is exerted upon the blood platelets, 
giving rise to a symptomatic purpura haemorrhagica i.ej
i
Group II, in contrast to Group I where he states !
"there is no bleeding from the mucous membrane - i.e. j  
a non-thrombocytopenic purpura." |
But haemorrhage can, and does occur in the absenci 
of thrombocytopenia. Thrombocytopenia cannot therefore)
i
be regarded as a sine qua non in relation to haemorrhage. 
In my own series of six cases, the platelet count
in/
in two instances was within normal range and yet haemor­
rhage occurred and in the case reported by Hudson (1936), 
the blood film showed an absence of platelets three 
days after the cessation of haemorrhage.
Scarborough and Stewart (1938) have reported one 
case in which the platelets numbered 500,000 with the 
presence of epistaxis, haematemesis and extensive 
petechial haemorrhages.
MacKay states that it is very doubtful if the 
thrombocytopenia is the cause of the characteristic 
lesions in purpura haemorrhagica and that the platelet 
diminution is merely a superimposed phenomenon. This 
writer*s researches also led him to conclude that the 
most important factor in controlling spontaneous
i
capillary haemorrhage or duration of bleeding time is j 
not the number of platelets in the circulation, but |
the ability of the vessel wall to contract. MacKay j
!
considers that the haemorrhages in purpura haemorrhagic|a
i
are due to a defect in the capillary wall.
Tidy (1928) suggests that so. long as the endo­
thelium remains intact no haemorrhage will occur even j 
in the absence of platelets, but when damaged, then the; 
deciding factor will be the number of platelets avail­
able for protection of the endothelium.
Bedson (1922) whose work has already been quoted, 
concluded that the main factors concerned in haemorrhag|e 
were/
were a toxic action on the endothelium of the vessels, 
and the removal of platelets from the circulation.
The foregoing evidence is sufficient to indicate 
that the absence or reduction of platelets in the 
circulation is not the sole factor leading to purpura 
haemorrhagica.
In considering the question of thrombocytopenia 
it would be expedient to refer now to the investigations 
carried out by certain workers as to the cause of the 
decrease in the number of platelets.
In thrombocytopenic purpura of unknown origin, it 
is recognised that removal of the spleen is frequently 
followed by a great improvement in the condition.
In view of this, certain workers have 3et out to 
establish the presence of a platelet reducing agent in 
the spleen. j
in 1938 Troland and Lee reported the presence of s|
I
platelet reducing principle in acetone extracts of !
I
spleens from patients suffering from thrombopenic 
purpura; when given intravenously to rabbits, these 
extracts lowered the count of the circulating platelets
Several workers have attempted to confirm these 
findings by Troland and Lee.
Major and Weber (1939) failed to obtain similar 
results with splenic extracts from two cases of 
thrombopenic purpura.
Watson (1941) after a series of experiments with 
splenic/
32.
splenic extracts from three cases of thrombopenic j
i
purpura injected into rats and rabbits, failed to find | 
any evidence to substantiate the existence of a specific
j
thrombopenic factor. |
Hobson and Witts (1940) however obtained a fall 
in the number of platelets in the rabbit with an acetone 
extract of the spleen from a case of thrombopenic j
purpura. j
It appears from a study of the literature that a !
iI
fall of platelets can occur in the rabbit when spleen j 
: | 
extracts are administered intravenously, but the effectj
is inconstant, and results obtained in these investi-
| gations are conflicting.
Arsenobenzol Compounds in relation to the Blood Coagu­
lating Mechanism.
The process of normal coagulation is still im­
perfectly understood.
Of the current theories that of Howell is the one 
most generally accepted. The essential factor in the 
process is the conversion of soluble Fibrinogen into 
the insoluble fibrin.
Fibrinogen is a type of protein which is formed 
i in the liver. It is well known that the Arsphenamines 
i are capable of seriously interfering with the function j 
of the liver cells, and it may be that the haemorrhage 
is/
is due to the destructive action of the arsphenamine 
upon the fibrinogen or perhaps to a lack of production 
of fibrinogen as a result of liver cell damage.
Flandin and Tzanck (1921) appear to have been the j
i
first to make known the anticoagulative action upon \
i
the blood of the arsenobenzols, both in vitro and
i
in vivo. These authors state that in vitro, if the !
blood is collected in a glass vessel, the sides of I
which have been moistened with a weak solution of 
arsenobenzol solution it will remain incoaguable in- |
definitely, in vivo, when the blood i3 taken from an !
individual who has received an intravenous injection ofj 
an arsenobenzol, it will be observed, that the coagula­
tion of the blood is delayed, and that this delay will 
last from 30 minutes to 24 hours or longer. If further 
samples of blood are taken, incoagulability continues \ 
for a period varying from a few hours to several days, 
the phenomenon then gradually passes off. I
Flandin and Tzanck also state that the anti-
j
coagulating action does not appear to depend upon the j
quantity of the drug injected, but the action appeared j
j
to be more sustained in those patients who had received 
a great number of injections in a series.
According to these authors the anti-coagulating 
effect is due entirely to the arsenobenzol, and has
ii
nothing to do with the syphilitic toxin. They state I
I
that the arsenobenzols do not seem to act on the blood 
corpuscles/
corpuscles or platelets of the blood which are not 
modified in form or number.
Anwyl-Davies and Mellanby (1923) found that the 
addition of one part of arsenobenzol to a thousand 
parts of blood prevents the coagulation of blood in 
vitro, and that therapeutic doses, used in clinical 
cases, have practically no effect on blood coagulation 
except to a small degree after long courses of adminis-j 
tration. j
I
According to these authors, the experiments in j  
vitro indicated that the anticoagulant effect of arsend- 
benzol was exerted on the last phase in blood coagula- j 
tion i.e. on the action of thrombin on fibrinogen.
As a result of their experiments they conclude that the 
combination of the arsenobenzol with fibrinogen depend^ 
upon the organic grouping, since arsenious oxide has 
no effect on the coagulability of the blood, nor does 
arsenobenzol combined with glucose (stabilar3an) alter | 
the blood coagulation. In their clinical observations 
they found that therapeutic doses of the various 
Salvarsan preparations intravenously injected into 
men or women have practically no effect on the coagul­
ability of the blood.
As a result of these investigations it may be 
concluded that the administration of arsenobenzol 
compounds over a prolonged period of time tend to have
a slight anticoagulative action upon the blood. These 
compounds used in normal therapeutic doses may be said 
to have a negligible effect in the aetiology of post- 
arsphenamine purpura.
|
t
Capillary Fragility in relation to Post-arsphenamine. 
Haemorrhagica.
Bell, Lazarus and Munro (1940) studied the effect^
of the ingestion of vitamin C in capillary fragility, j
|
The fragility of the capillaries of the skin of j 
the anti-cubital fossa was examined by Gothlin*s methodj.
Large doses of vitamin 0 were given to thirty-fivej 
subjects after their capillary fragility has been esti-j 
mated. The capillary fragility was estimated fourteen | 
days later. Of twenty-one cases with original values j
of eight or more petechiae the vitamin treatment was
! I
followed by a reduction to the values of eight or under
i
in sixteen cases. j
In fourteen cases showing originally less than 
eight petechiae vitamin C had no effect on the number
i
i
of petechiae.
In their series of 346 cases these authors found 
five subjects with an initial count above eight, and nc 
response to the first treatment with ascorbic acid,
1 were found to resist a further ten days course of 
200 mg. of vitamin C daily.
These five subjects were given large doses of 
vitamin/
36. j
I
vitamin P (Hesperidin) without producing any change inj
the capillary fragility. |
I
These authors conclude from their investigations j
that:- ii
(1) when the petechial count was eight or over, the 
ingestion of vitamin C reduced the petechial count j
i
to less than eight in two weeks.
(2) The ingestion of vitamin G has no effect on petechija 
counts below eight.
(3) There are a few healthy persons (five in 346) with 
increased capillary fragility which is not in­
fluenced by the administration of vitamin C or 
vitamin P.
(4) Apart from abnormal influences, e.g. fever, and the 
administration of heavy metals, two factors in­
fluence capillary fragility in normal health: 
menstruation, and ascorbic acid.
They also conclude that their investigations lead •! 
to the suggestion that other factors are involved.
Scarborough and Stewart (1938) in their experiments 
showed the value of vitamin P (hesperidin) in the treat­
ment of purpura occurring as a toxic manifestation of j 
antisyphilitic therapy with arsenic. They found that 
the subjects examined had a low capillary resistance, 
and that this was raised by the administration of 
vitamin P.
Horne and Scarborough (1940) believe that vitamin
P/
P is a factor in increasing the capillary resistance | 
and publish the result obtained in the case of purpuricj 
haemorrhagica following arsenobenzol treatment. j
After the administration of vitamin P, clinical improve­
ment was noted and no further petechial haemorrhages 
developed. I
Scarborough (1940) as a result of his studies in | 
deficiency of vitamin 0 and vitamin P in man states that 
alow capillary resistance in people with various forms
i
of nutritional deficiency was found to be associated 
with a deficiency of vitamin P. This author points 
. out that it is possible that some forms of purpura may j
i i
; have a nutritional basis. I
j
|
| SBCTIOM IV- COBCAjUSIQMS FKQM CASKS KhVIEWED.
From a study of the foregoing thirty-six cases, 
together with literature relevant to this subject, 
it may be concluded that:-
(1) Post-arsphenamine purpura is a comparatively rare 
complication in the treatment of syphilis.
| 12) In the absence of accurate knowledge as to the 
aetiology of the condition, the present class­
ification can only be provisional* This would 
appear to be due to an endeavour on the part of 
some observers to establish post-arsphenamine 
purpura/
38.
purpura as a clinical entity, whilst others regard,
i
it merely as a part of a more complex disease. j
^3) The Drug. In the cases reviewed Neoarsphenamine j 
was the drug chiefly responsible but this is pro- j 
bably because of its more frequent use, and if
I
sulpharsphenamine had been used to a similar extent 
more reactions with the latter drug would have 
occurred. It is not possible, however, to state 
definitely which drug is most frequently associate^ 
with post-arsphenamine purpura.
(4) The number of injections, the particular dose, or 
the total amount of the drug given, do not appear 
to be important factors in the aetiology. The 
complication,however, generally occurs after 
several injections of arsenic have been given, the 
patient apparently developing a sensitivity to the 
drug.
^5) Prodromal symptoms are frequent and were present 
in 61 per cent of the cases reviewed.
(6) Thrombocytopenia i3 not the primary cause of the 
complication. Post-arsphenamine purpura may occur 
in the absence of thrombocytopenia.
(7) In those cases where there is a marked diminution 
in the thrombocyte count, the haemorrhage tends tc 
be more severe.
(8)/
Therapeutic doses of arsenobenzol compounds do not 
have any significant anticoagulative action on the 
blood. |
A deficiency of vitamin and *0* has been found 
associated with a low capillary resistance in 
cases of post-arsphenamine purpura. It has been 
suggested that a vitamin deficiency may be a 
responsible factor in some cases of purpura.
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SECTION I . TECHNIQUE EMPLOYED. j
I
BLOOD EXAMINATION. j
Enumeration of the red and white blood cells was j
l
done by means of the Thoma haemacytometer. Hayens 
solution was used in the case of the red cells, and 
the diluting fluid for the leucocytes consisted of 
1 cc. glacial acetic acid in 100 cc. of distilled j
water, to which methyl green was added.
The haemoglobin estimations were carried out by j
i
means of a Sahli haemoglobinometer. j
The stain used for the Differential Count of the !
j
white cells was Jenner-Giemsa. j
Enumeration of Blood Platelets and reticulocytes j 
was performed according to the method suggested by j
William Dameshek (1932). The diluting fluid consisted j
!
of a 3.5 per cent sodium citrate with sufficient j
brilliant cresyl blue stain added to give the solution j 
a bright blue colour.
The bleeding time was estimated according to 
Duke’s method, and Lee & White’s method was adopted in; 
the estimation of the coagulation time.
A mercurial Baumanometer was used for the Blood Ii
pressure readings. Smears and cultures were examined j 
and reported upon by the Clinical Bacteriologists to j
I
the Venereal Disease Department at the Hoyal Infirmary ! 
Edinburgh.
The/
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The capillary resistance was determined by a j
positive pressure Technique. The arm cuff was applied I
i
to the upper arm and the pressure was quickly raised j
i
to 100 mm. Hg. and maintained for five minutes. At th^
i
end of this time the number of petechiae on the whole j
i
arm below the cuff were counted. !
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SECTION II.
i
CASE I. A female aged twenty -four, married, with one j 
child eleven months old. She looked a healthy 
person* and weighed @ st. 8 lbs.
The patient reported to the clinic on the 2nd February 
1932 and she had suffered from genital sores for two 
months previous to reporting at the clinic.
The Blood Wassermann test was strong positive.
On examination the patient was found to suffer from 
numerous condylomata around the anus and on the labia. 
The inguinal glands in both groins were enlarged.
The tonsils were enlarged and there was some congestion 
of the throat present, with a mucous patch on the right 
tonsil.
Treatment.
2.2.52 until 5.5.52. 12 weekly injections of 0.3 gm.
Keo Kharsivan. At the end of this series of injections 
the patient complained of dizziness and pain behind 
both ears•
6.6.52 until 5.10.52. 15 injections (mostly given at
weekly intervals) of 0.3 gm. Bismuth (Hjjrboloid B.W.)
At the end of this period the blood Wassermann test 
was negative. I
5.12.52 until 15.5.55. 10 injections at periods varying
from seven to fourteen days. The first of these in­
jections was 0.15 gm. Kharsulphan, the second was 0.15 
gm. Neokharsivan, and the rest were 0.3 gm doses 
Kharsulphan.
After the second dose in this series, that is 
after the 0.15 gm. Neokharsivan the patient complained ' 
sickness immediately after the injection. It was 
noted that the patient had lost 4^ lbs in weight since i 
beginning treatment.
From 20.5.55 until 14.8.55. 15 injections of Bismuth !
totalling 4.35 gms.
From 7.10.35 until 25.11.55 patient received
|
1 injection of 0.15 gm. Kharsulphan 
and 4 injections of 0.3 gm. Kharsulphan.
History* i
On 2^12.53 the patient reported at the clinic and ! 
stated that she had bleeding from the gums. This had 
occurred about two hours after each of the last two 
injections, but she had not mentioned it at the clinic. 
On being questioned the patient admitted that a similar 
bleeding had occurred a year previously.
Examination.
On examination purpuric patches were observed on 
both arms and legs. These were for the most part on 
the flexor aspect of the forearms and on the front of 
both thighs. These varied in size, some were only 
petechial spots whilst others were the size of a 
shilling. A very large purpuric patch 3§ inches in 
diameter was present over the left biceps muscle.
The gums were spongy and inflamed, with pus oozing
from some septic roots of teeth present.
There/
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There was a moderate amount of bleeding from the gums,
starting in the lower jaw* the breath was foetid, and
the throat wa3 congested and the tonsils enlarged* 
Circulatory System* The heart sounds were normal.
There was no cardiac enlargement. Blood Pressure 120/68* 
The pulse and temperature were quite normal.
Abdomen. Examination of the abdomen was negative.
' Nervous System. Wo abnormality detected.
Urinary System. The urine was normal, no trace of 
albumin had ever been present throughout the treatment.!
A blood examination was done on the 2.12.S3 the result ! 
of which is given. j
(See Table) ij
|
Capillary Resistance. A tourniquet applied for five 
minutes at 100 mm. Hg. pressure, produced numerous smaljl 
petechiae showing the presence of an increased fragility 
of the capillary walls..
Bacteriological Examination. !
A culture was prepared from pus taken from the 
gvims, this showed a non-haemolytic streptococcal growtli, 
and staphylococcus albus. A smear was also examined 
and this showed numerous fusiform bacilli, a few spiro*r 
chaetes and gram positive cocci# ;
Treatment.
This patient refused to remain in hospital for 
further observation but she was given calcium chloride 
by/
46.
by the mouth (gr. XV thrice daily), she made a oompletje 
recovery, and no further arsenic was administered* I
SUMMARY OF CASE.
— !i
Total arsenic given over period of twenty-two months !
7.2 gms. |
Nature of arsenical preparation 3.6 gms Kharsulphan !
|
and 3.6 gms. Neokharsivan. |
Patient had marked symptoms of intolerance prior to 
onset of purpura.
Mild thrombocytopenia present•
Bleeding time slightly increased.
i
A toxic focus of infection was found present in the 
teeth and gums, at the time of the onset of purpuric 
symptoms•
i
!
CASE 2. The patient was a female aged 66, unmarried* j
j
Her weight was 6 st. 2 lbs. j
In March 1932 the patient was sent to The Royal Infirmeiry
j
Edinburgh by her doctor because of a swelling on the j
lower lip of two months duration.
The blood Wassermann test was found to be strongHy |
f
positive.
Antisyphilitic treatment was started on 29.3*32.
From 29.5.52 until 21.7.32. 13 weekly injections of j
Kharsulphan were given, all were 0.3 gm. doses except 
the first which was 0.15 gm. During this period four­
teen weekly injections of 0.3 gm. Bismuth (Hypoloid 
B. W. & Co.) were also given.
After this the patient had no further injections for 
a period of two months. j
From 12.9.52 until 17.11.32. 10 weekly injections of j
Kharsulphan were given, all doses were 0.3 gm. except ; 
the first which was 0.16 gm.
The blood Wassermann test was now negative.
From 12.1.35 until 20.4.55. 15 weekly injections of
0.3 gm. Bismuth (Hypoloid were given. The patient at 
this period of her treatment felt very well and 
gained 3 lbs in weight.
From 15.6.33 until 6.7.55. 5 weekly injections of
Kharsulphan were given, all 0.3 gm. doses except the 
first which was 0.15 gm.
On 10.7.55, that is three days after the last injection 
of Kharsulphan the patient reported at the clinic, with 
marked purpuric haemorrhages. On being questioned the 
patient stated that she had vomited clots of blood and 
passed blood from the bowel the day following her last 
injection of Kharsulphan. She was admitted to hospital 
and given Calcium Lactate gr. XV every four hours.
Examination.
This revealed purpuric haemorrhages on the buttockjs
|
end legs. The largest of these was about the size of j
i
a half crown, and the haemorrhages were more marked on j 
the flexor aspects of the legs.
There was no bleeding from the gums. There were several 
decayed/
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decayed teeth present, but the mouth was not in a
septic condition* The tonsils were enlarged, and some-*
what congested, and some thin pus could be expressed
from both tonsils. The patient admitted that she had
frequently suffered from "sore throat".
The pulse, temperature and respiration were all normal.
Circulation. (1) There was no history of rheumatism or
other illness to account for the 
presence of the valvular lesion. ?
(2) There were no symptoms of cardiac 
involvement.
(3) The Blood pressure reading was systolic 
160, diastolic 88. (
(4) Over the apex a distinct presystolic 
murmur was audible.
Abdomen. The spleen was not palpably enlarged, and no |
abnormality could be found in the abdomen. j
Rervous System. Ro abnormality.
Urinary System. Ro abnormality.
On 11.7.33 the patient passed a considerable amount of 
blood in the urine and conjunctival haemorrhages were 
present. She looked pale and she was suffering from 
shock. The pulse rate was 120, temperature 96.8, and
i
the respirations rapid. A blood transfusion was givenj 
at 6 p.m. and the patient almost immediately looked 
better.
A blood examination was done on admission.
(See Table)
49.
On 12.7.32 an enema was given, and the patient passed 
a large quantity of dark brownish red blood in the 1 
stool. No fresh external haemorrhages had occurred, 
and the pulse was satisfactory. During the afternoon 
the patient vomited a little dark brown blood.
At 6 p.m. the patient was again transfused with one 
pint of blood. The pulse rate rose to 112, and the 
temperature to 100.6 at 7 p.m. At 7.20 p.m. she was 
given 1/3 gr. omnopon, and thereafter passed a comfort­
able night.
On 13.7.33 the patient seemed better, a large haematoma 
had developed at the site of the hypodermic injection. 
The temperature was 99.2°F. and the pulse rate 104. 
Blood was still present in the urine and f aeoes.
On 14.7.33. Very little change was noted.
The pulse rate however increased, and the temperature 
was 100°F. There was 3ome diarrhoea and the stool 
contained blood. In the evening the abdomen was much 
distended. The pulse remained fast, the patient looked, 
very pale and her respirations were laboured and rapid. 
At 9 p.m. she was transfused with 1 pint of blood and 
5 cc. pernaemon.
On 15.7.33. The patient appeared to have improved agairj, 
the pulse rate was 96 and temperature 97.6®F. The 
respirations were easier and normal in rate. Blood wad 
still present in urine and faeces. '
On/
50.
On 16.7>55. A larg© quantity of* blood was passed per
rectum, and the urine also contained blood. The patient
was much weaker* She became progressively worse, the
pulse was very feeble, and the patient was sick and
vomiting. A further blood transfusion and 5 so. pernaemon*
was given.
This time however the response was not so marked. The 
patient was then given a rectal lavage, followed by a 
starch and opium enema.
17.7*55. An improvement was again noted in the 
patient*s condition. The pulse was full and strong 
and the temperature and respirations were normal.
A further colon lavage was given and thereafter a 
starch and opium enema. A very large quantity of blood 
was returned.
5 cc. pernaemon was given along with a transfusion of ; 
blood at 7.30 p.m.
i
19.7.55. The patient was fairly comfortable, pulse 
good and the temperature was normal. The urine was 
practically clear of blood, only a few red blood cells j  
were found in a centrifuged deposit. The abdomen how- !
i
ever was very much distended, and the patient was
j
frequently sick. She was unable to take any fluids
by the mouth. j
A starch and opium enema was given, and again a great j
i
quantity of blood was returned•
5 cc. pernaemon was given and also 0.5 cc. pituitrln 
at 8 p.m. The patient became much distressed at 
9.30/
9.30 p.m. and a further 0*5 cc* pituitrin was given*
1/6 omnopon was also given. The patient however failed 
to respond. She vomited frequently, gradually became 
comatose, and died at 5.55 a.m on the 20.7.33. 
Post-mortem Findings. Mo obvious oedema present.
A marked purpuric rash was present on the lower limbs•
Kespiratory System. The lungs were emphysematous, and 
in addition they showed a certain amount of terminal 
oedema.
Oirculatory System. Externally, the heart showed one 
or two t^ny subepioardial haemorrhages over the coronary 
sinus posteriorly. The myocardium throughout the heart 
was thin, pale and friable. Subendocardial haemorrhages 
were present in the wall of the left ventricle, and in ! 
the papillary muscles.
Alimentary System. A good deal of altered blood was 
present in the lumen of the large gut. Mo definite 
bleeding point was detected anywhere in the alimentary : 
tract, the blood evidently being the result of a 
general capillary oozing. The liver showed a moderate 
degree of chronic venous congestion. !
Genlto Urinary System. There was no evidence of chronic 
kidney disease. The right kidney near the upper pole | 
was the site of a number of small haemorrhages in the 
cortex. The pelves showed a good deal of submucous 
haemorrhage•
H aemopoietic System. Bone marrow from shaft of the 
femur showed only very slight indication of reaction. 
The microscopic examination showed a very strong 
erythroblastic reaction. Nucleated reds were present 
in all stages from stem cell downwards, the majority 
being in the normoblastic stage. A moderate leuco- 
blastic activity was in progress.
There was a large number of megakaryocytes both 
degenerating and in the process of formation. These 
cells were present in greater numbers than they would j 
have been in pernicious anaemia. -
The spleen was rather large, moderately soft in con- j
i
sistence and of a bright red colour. j
Connective Tissue. The retroperitoneal areolar tissue j
throughout the abdomen showed numerous small areas of \
!
haemorrhage• j
I
SUMMARY OF CASE.
Total amount of arsenic given over a period of sixteen 
months was 7.95 gms.
Nature of arsenical preparation - Kharsulphan only.
No indication of intolerance to arsenical therapy 
before the sudden onset of symptoms.
History of frequent sore throat. The tonsils were the 
seat of toxic infection.
Complete absence of platelets.
Bleeding time markedly prolonged.
Coagulation/
53.
Coagulation time slightly prolonged.
Transfused with one pint of blood five times in 
seven days.
Improvement in patient* s clinical condition after 
each transfusion. j
i ii
|
CASE 3 . This was a female patient aged 34* married*
with two children. !
She was very obese weighing 15 st. 2 lbs. Her menstrual)
periods had always been scanty and irregular*
every ten weeks.
After the birth of her second child in 1929, she de- j  
veloped puerperal fever, and at this time she had a i
i
large septic sore near the anus* which burst* with a 
profuse discharge of pus. i
She reported at the Skin Department of the Koyal Infirmslry 
in July 1932, and sought advice on account of redness
|
and irritation in the region of the urethra. j
A large tertiary cutaneous lesion was present on the j
I
face* spreading over both cheeks and forehead. j
i
/
The Wassermann test was found to be strong positive.
Treatment. On lg.7.52 The patient received her first j  
injection of 0.15 gm. Neokharsivan and on the 25.7.32 j 
she received 0.3 gm. Weokharsivan.
From 1.8.32 until 51.10.32, 10 weekly injections of 
Kharsulphan were given, all being 0.3 gm. doses except 
the first which was 0.15 gm.
13/
occurring)
13 weekly injections of 0.3 gm. Bismuth (Hypoloid) was 
also given during the 3ame period. The patient com- j 
plained of dizziness after the 5th dose of Kharsulphan,; 
but the dose of the drug was not reduced. \
From 23.1.33 until 15.5.33. 11 injections of Khar­
sulphan were given at somewhat irregular periods owing ; 
to teeth extraction. One of these was given after 
an interval of twenty-eight days, three others were 
given at fortnightly intervals, all were 0.3 gm. doses ;
i
except the first which was 0.15 gm. !
From 7.8.35 until 20.11.35. 15 injections of Bismuth
Hypoloid) all 0.3 gm. doses except the first, this I 
being 0.15 gm. j
The Wassermann reaction was now weak positive. |
From 8.1.34 until 22.1.54. 3 weekly injections of j
i
Kharsulphan, first one being 0.15 gm. dose, the others 
being 0.3 gm. dose3. j
j
The patient reported to hospital on the 5.2.34, com- j
i
plaining of bruises on her arms and buttocks• She said
I
that about two hours after her injection on the 15.1.34, 
she saw small red spots round the neck, and on the. right 
arm, after she went home; in the afternoon she felt 
shivery and became feverish at night. She also stated 
that half an hour after her injection on 22.1.34 she 
had experienced a shivering, with severe headache, and j
i
pain in the back. j
Examination./
Examination 5.2*54. The patient looked anaemic and
I
she had greyish unhealthy pallor. She was verjr obese 
and suffered from dyspnoea. Her temperature was normal, 
the pulse rate 96, respirations were normal. There 
wa3 some tenderness over the frontal sinuses, especially 
on the left side. Small purpurio spots varying in size 
from one to five millimetres in diameter were presemt 
on the neck, chest and left arm, and large purple 
bruises were present on the left wrist,and over the 
left buttock. There were a few fresh purpurio haemo- 
rhages present over the flexor aspects of the lower 
limbs.
The throat was red and congested. The tonsils had been
I
removed some years previously but pus could be expressed 
from the tonsillar region. A throat swab was taken
and this showed haemolytic and non-haemolytic strepto- j
cocci (the latter predominant). j
Staphylococcus albus and coliform bacilli present j
i
on culture. j
iI
There was no bleeding from the gums or other mucous 
membranes.
No blood present in urine or faeces.
ij
Circulatory System. The Blood pressure reading was 
systolic 140, diastolic 72. The heart borders could 
not be defined owing to the patient*s obesity. j
i
The heart sounds were of a slapping nature indicating 
early/
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early myocardial damage but no valvular leakage could ! 
be detected.
Nervous System. No abnormality.
Abdomen. Nil to palpation.
The urine was perfectly normal.
The patient had not lost any appreciable weight during 
her treatment.
(See Table)
This patient was allowed to go home# as she resented 
hospitalisation. She returned on 14.2 *34> and apart 
from a few fresh petechial haemorrhages on the heck* 
her general condition had improved. She made a spont­
aneous recovery.
SUMMARY OF CASE.
A mild case of purpuric haemorrhage with no re­
duction in the number of platelets.
Total amount and nature of arsenic given over a period 
of eighteen months
Neokharsivan 0.45 gms. ]
i!
Kharsulphan 6.75 gms. |
Premonitory symptoms were present in the form of giddi­
ness, shivering, headache and haemorrhagic spots.
i
The patient suffered from sore throat for ten days pridr
i
to the onset of her symptoms. A focus of infection was!
found to be present in the throat.
There was no abnormality present in the blood.
The blood platelets were not reduced in number.
CASE 4. The patient was a male aged 29. He weighed j
8s t •Si'.iha . He reported to the Royal Infirmary 
on i l arKi he was found to be suffering from gross I 
oedema of the prepuce and a purulent sub-preputial j 
discharge.
On 7.7.55 spirochaete Pallida were found present in 
■^ he discharge. There was enlargement of the inguinal 
glands on the right side. Otherwise the patient appealed 
to be well. j
Treatment. From 11.7.33 until 29.9.33 the patient was j
|
given nine injections of Neokharsivan, all were 0.45 gnk. 
doses except the first and the last which werd 0.3 gm. 
doses. During this period he received 3.8 gms. Bismuth 
(hypoloid). '
From the 3.11.33 until 24.11.35> three injections of j
neojfeharsivan were given, each dose being 0.45 gms. j
During this time four injections of 0.3 gm. Bismuth i
were given.
On 26.11.33» that is, two days after his last injectioii
j
of Neojcharsivan, when blowing his nose it started to 
bleed. It continued to bleed all night fairly pro- j
fusely. The following evening the patient noticed j
•red spots" on his legs. j
He was admitted to hospital on 29.11.33.
Examination. The patient was very thin, and under- j
sized. He was pale but not markedly so. His pulse
rate/
rat© was 88. Temperature subnormal and respirations
normal• There was a widespread purpura eruption on
the upper part of the front of the chest, and over the
shoulders. There were a few diffusely scattered spots
on the thighs and legs. Their size varied from one to 
in. diameter.
three millimetres^ There was considerable oozing of 
blood from the nose and mouth. Haemorrhagic blebs 
could be 3een on either side of the nasal septum.
These were also present inside the mouth, at the sides 
of the tongue, inside the lips, and also on the surface 
of the tonsils. There was also some oozing round the 
roots of the lower teeth. The tonsils were difficult 
to demonstrate, these being submerged, but a small 
amount of pus was expressed from the left tonsil. The 
tonsillar glands on both sides of the neck were swollen. 
The upper teeth were artificial while the lower teeth 
were septic, the gums were red and painful to touch - 
they bled easily. The tongue was coated and furred. 
Cultures from the gums showed a growth of diphtheroid 
bacilli and non-haemolytic streptococci. Cultures made 
from the tonsillar section showed staphylococcus albus 
and a good growth of non-haemolytic streptococci.
Cardio-vascular system. The blood pressure reading wasj 
130/68. The pulse was regular, and of low tension. j 
The heart was not enlarged, and the heart sounds were j
pure.
Nervous/
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Nervous System* There was no abnormality discovered 
in the nervous system.
Abdomen. Spleen was palpable just in front of the 
anterior axillary line. The liver was not enlarged 
and there was no evidence of any other abdominal 
derangement.
Respiratory System. The chest was thin and there was 
a slight tendency to pigeon chest. The respiratory 
excursion was poor. Slight dullness was present over
the upper left lobe in front. Over the right upper
o !
lobe the breath sounds were vesicular with median j
crepitations and rhonohi. Over the upper left lobe j 
there was medium pitched bronchial breathing with j
rhonchi and over the left apex fine crepitations were j 
present.
Urinary System. The urine was normal in every respect.I
Blood Examination. (see Table) j
|
I
This patient was transfused with 12 ozs. of blood j 
on 30.11.33, and on that date a splenectomy was per- | 
formed. He had a further transfusion on 1.12.43 of 
14 ozs. of blood. He made a satisfactory recovery and 
he was discharged on 16.12*33 to continue his treatment 
as an out-patient.
SUMMARY/
60.
SUMMARY OF OASIS.
The patient received 5.2 gms. Neokharsivan over a period 
of four months.
The onset of symptoms occurred two days after hie last 
injection.
i
At the time of the onset of symptoms a focus of toxic ! 
infection was present in the teeth and gums. j
The spleen was slightly enlarged. j
Splenectomy was performed, and he made a very satis- j
factory recovery. j
j
In March 1934 this patient was discovered to be suffer-j
I i
ing from Pulmonary Tuberculosis. Tubercle Bacilli were; 
present in the sputum. He was then transferred to a j  
hospital for the treatment of tuberculosis. j
CASE 5. The patient was a female aged 43. Her weight 
was 7 stones 1 lb. She was reported to have: 
been a healthy child. As an adult her health 
had been on the whole satisfactory. Her periods were 
regular and normal. Apart from occasional sore throats, 
she was not subject to minor ailments.
The lower teeth had been extracted three years previously 
because of pyorrhoea. j
j
The patient reported to hospital on 27.7.33 with numer-j
;
ous gummatous ulcers around, and under the right knee* | 
The/
The blood Wassermann was positive, and the Gonorrhoeal ,
Fixation Test gave a weak positive result. j
ii
Treatment.
51.7*55 until 25.11.55. 16 injections of Neokharsivan
were given,at more or less weekly intervals, in one
instance there was a lapse of three weeks, and the last!
|
three injections were given within a period of eight j
j
days. The entire series of injections were made up j 
as follows:
ii
8 doses of 0.15 gm. each. j
4 " * 0,2 gm. * |
4 * *» 0.3 gm. " |
After the eleventh injection of the series a trace of j 
albumin appeared in the urine. This disappeared the j 
next day and the urine remained free from albumin !
during the whole of the patient*s treatment.
After the second injection of 0.15 gm. Meokharsivan, 
the patient stated that her left eye had become swollen 
and inflamed, on the evening of the injection. On the ; 
following day the eye was i^ uite normal. Otherwise 
there was no untoward effect, and the patient had gained 
7 lbs. by the end of her course of treatment. j
13 intramuscular injections of Bismuth (Hypoloid B.W.) j
|
were given over the same period of time * each dose i
!
being 0.3 gm. j
From 21.12.55 until 5.4.54 the patient received fifteen 
weekly doses of 0.5 gm. Bismuth (Hypoloid). I
0n 10*5.54 ^ e  Wassermann test was still positive and a 
lumbar puncture was performed.
On 50.5.54 as the patient suffered from headache and 
a general malaise after this no further antisyphilitic 
treatment was given for a period of three weeks. 
Examination of the cerebro-spinal fluid yielded a normail 
result•
From 22.6.34 until 16.8.34 the patient received nine 
weekly injections of Kharsulphan, all 0.3 gm. doses 
except the first which was 0.15 gm. At the end of this> 
series a boil developed on the left buttook, and she 
also suffered from a patch of infective dermatitis below 
the left knee. There was also some patches of sebor- 
rhoeic dermatitis over the chest and back. Whilst the 
skin condition was treated the patient received no 
further arsenical injections.
On 11.10.54 an injection of 0.15 gm. Kharsulphan was 
given, followed by four similar doses at weekly intervals. 
It was noted that the rash on the body and behind the 
knee became worse after each injection of Kharsulphan, 
and in view of this, arsenical treatment was stopped 
meanwhile•
On 25.1.35, when the patient reported to hospital she 
complained of a sore throat. The throat was found to 
be congested, and the tonsils were much enlarged and 
septic/
septic. There were ulcers present in the mouth.
A throat swab showed a growth of nob-haemolytic strepto­
cocci and staphylococcus albus. Six weeks later his 
general condition was much improved. The throat and 
tonsils looked normal, and the skin condition was 
vastly improved.
From 7.5.55 until 11.7.35 15 injections of Bismuch
(Hypoloid) were given in 0.3 gm. doses. On the 14.3.35 
the patient again complained of sore throat.
From 28.8.35 until 17.10.55 15 biweekly injeotions of
1 cc. colloidal calcium were administered.
0n 24.10.55 the patient received 0.075 gm. Kharsulphari, 
that is, ten months after her last injection of arsenic. 
A week later (51.10.35) 0.15 gm. Kharsulphan was given, 
and a further dose of 0.15 gm. Kharsulphan was given 
on the 7.11.35.
One hour after this third and last injection of Khar­
sulphan, the patient stated that she felt "queer", and 
that she commenced to shake. When going to bed the 
same evening, (12£ hours after her injection) she I
noticed some "red blisters" inside the lower lip.
At 11 a.m. next day, (twenty-four hours after the in- j
jection) she noticed a swollen area on the back of her i
j
right hand,and the same evening other bruised and j
!
swollen areas appeared on her arms and legs•
Unfortunately the patient did not report again until 
seven days after her injection. She was admitted to 
hospital/
hospital and the following evidence of haemorrhage was 
noted and further investigation of the condition made.
Examination. Numerous areas of haemorrhage were noted 
and these are summarised below:
TABLE IV.
Position of Haemorrhage._________ Extent.
Posterior aspect right elbow One inch diameter.
Dorsal aspect left wrist i inch diameter.
Dorsal aspect right hand Haemorrhagio Spots 
one to three m.m. 
diameter;.
Lateral aspect right leg 
extending from knee to 
ankle•
Large bruised areas 
fc-2 inches diameter.
i
Flexor aspect left leg Petechial haemorrhages i 
only •
The patient had not been aware of any bleeding from
the nose or gums, she had not noticed any blood in the j 
urine or stools.
She looked very pale, and complained of vague pains in | 
her arms and legs. Her weight was now 7 stones 5 lbs, i 
still 4 lfcs heavier than when she started antisyphilitijc 
treatment. j
Her temperature was 97.4. The tongue was dry and furrefi,
i
and she stated that she had suffered from constipation i 
for several months and that she had no appetite.
The throat was much congested, and the tonsils were 
enlarged/
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enlarged and soft. Pus was expressed from both tonsils. 
| The posterior pharyngeal wall was dry and congested. j 
Ked raw patches were present on the palate. A swab 
I from the throat showed a moderate growth from haemo- 
| lytic streptococci, and staphylococcus albus, with a 
scanty growth of diphtheroid bacilli.
Cardio-vascular system. The Blood pressure was
systolic 110, and diastolic 90. The pulse rate !
was 92 per .minute. There was a little irregularity of | 
the pulse, and it was of poor volume. Examination of 
the heart revealed no enlargement, the sounds were |
j
pure, but there was evidence of myocardial damage, j
i
the irregularity of the pulse was due to extra systolesj.
Hespiratory system. There was no abnormality found on j
—" ! 
percussion. A few rhonchi were present at the right j
base• !Il
I
Rervous system. Ro abnormality detected. !
Abdomen. Hormal to percussion and palpation.
iUrinary system. The urine was q,uite normal. Only 
once during the treatment a trace of albumin was found 
to be present.
The result of the blood examination is given.
(See Table)
This/
This patient made a spontaneous and satisfactory re- 
I covery from the complication. She remained in hospitaJj
j for fourteen days. During this time there was no
! ij !
: further haemorrhages, and the haemorrhagic patches ;
j rapidly improved. j
Treatment with Bismuth was resumed on 2.1.36* her !
blood Wassermann being still positive. j
Since 2.1.56 until 24.9.42 the patient received 26.16 ^ms. 
Bismuth.
j She is still attending hospital. Ro further arsenio 
has been administered and there has been no sign of 
any further purpuric haemorrhage •
; i
| SUMMARY OF CASE. Oyer a period of twenty-six months
the patient received a total of 
b.87 gms. arsenic.
An intolerance to arsenic had been noted early on in
the treatment, in the form of an allergic reaction in
I '■
the skin. j
The patient was subject to sore throat, due to the un- j
healthy state of the tonsils, and a focus of infection |
was present in the tonsils.
Colloidol Calcium was administered for six weeks prior 
to the onset of purpuric haemorrhages •
A very small dose of Kharsulphan was sufficient to 
precipitate symptoms of purpura.
Blood/ !
Blood examination showed a leuoooytosis with an increase 
in lymphocytes. The polymorphonuclear cells were I
j
greatly reduced (28 per cent). j
A large quantity of Bismuth has been administered durirjg
!
the past seven years without mishap. j
i
CASE 6 . This patient was a female aged 47. Her weight
|
was 10 stone 7 lbs. She was married and j
. i
had six healthy children. Her only previous illness j
was a chole^cystectomy performed in 1926.
She first reported at the Eye Department of the 
Infirmary, and it was found that she had Argyll- 
Hobertson pupils, and an internal strabismus in the 
right eye. The blood Wassermann was found to be 
strongly positive.
The Gonococcal fixation test was negative.
Urethral smears were negative.
The cervical smears showed only pus cells - no GonooocoJ' 
were present.
From 6.2.54 until 12.4*54 the patient was given nine 
weekly injections of arsenic as follows 
1 Kharsulphan dose 0.16 gm.
1 Neokharsivan dose 0.15 gm.
5 Heopharsivan doses 0.3 gm. each.
1 Heopharsivan dose 0.2 gm.
1 Kharsulphan dose 0.075 gm.
During/
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During this period the patient also received 
seven doses of 0.3 gm. Bismuth (Hypoloid). 
j Immediately after the sixth injection of arsenic, that j
I is, after the fourth 0.3 gm. dose Neopharsivan, the j
i |
I patient vomited a little, but there were no other 
symptoms•
; Vomiting again occurred after the next injection in 
the series of 0.3 gm. dose Neopharsivan. Later again :
after her last injection of the series, that is, 0.076 | 
gm. doses of Kharsulphan the patient complained of I 
: nausea. j
From 24.4.34 until 9.6.54 the patient received eight j
i
injections of Bismuth only, each dose being 0.3 gm. I
0n 14.7.54 small doses of Kharsulphan were again 
commenced starting with two 0.075 gm. doses, six in­
jections of 0.15 gm. Kharsulphan were given. j
The patient received her last injection of Kharsulphan j 
on 8.9.34, and she complained of a discharging ear.
Pus was observed to be oozing from the right ear, and ,
that patient stated that this condition had been present
for the past two weeks. She was therefore sent to the ; 
Ear Department for treatment.
i
On 15.9.34, one week after her last injection, the i  j
patient reported to the Clinic with purpuric haemorrhages.
She was admitted to hospital. j!
|
Examination. The patient looked ill - her pulse rate j
was 100, temperature 97.2°F., and respirations normal.
She/
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She was very pale. The right ear was still discharging. 
| A swab taken from the ear showed a good growth of* j
I Staphylococcus albus, and coliform bacilli were present!.
| On culture Staphylococcus albus, and diphtheroids were I
i |
iobtained. ;
i  The throat was inflamed, the tonsils were enlarged,
i
congested, and pus could be expressed from the crypts. j
A swab from the tonsil showed on culture a profuse !
growth of streptococci viridans, and Staphylocooous j
: |
! albus• j
! i
Large purpuric pa^jes, mostly about the size of a  j 
|shilling, some slightly larger, were present on the j 
flexor surfaces of both arms, and on the thighs of bothj
legs. There was no bleeding from the mucous surfaces. |
|
It is noteworthy that the patient stated during the ! 
examination, that she noticed these spots beginning thej
j
day following her last injection - on 8.9.54. !
i
Circulatory System. The pulse was full, and there was ; 
slight thickening of the radial and brachial arteries. 
The blood pressure reading was systolic 170, diastolic 
100.
The left border of the heart was in the left nipple line 
and the apex beat was displaced downwards to the 0th 
interspace. A faint systolic murmur was heard over the
mitral area.
i
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Nervous System* The pupils reacted to accommodation* I 
but failed to react to light. The margin of the right j 
pupil was slightly irregular. In the right eye the 
presence of a paralytic internal strabismus was noted. 
The plantar reflex was flexor* the epigastric and 
abdominal reflexes normal. The knee jerks were absent* 
while the ankle* and biceps jerks were normal.
Komberg's sign was negative. Sensation was unimpairedi
I
Abdomen. The tip of the spleen was just palpable* |
otherwise no abnormality was detected.
Urinary System. There were no abnormal constituents j
present in the urine. !
fI
The findings in the blood examination are recorded* j
j
(See Table)
|
The patient had never lost weight. On 24.9.54* the j
patient weighed eleven stones. Two days after the j
appearance of the purpuric spots, a few more purpuric ;
patches appeared on the thighs, but no bleeding from |
the mucous membrane occurred. Treatment consisted in i 
the administration of Calcium Carbonate gr. XV thrice 
daily. The patient made an uninterrupted recovery, j
and she was allowed to go home on 6.10.54. She reported
i
regularly each week, but no further symptoms of purpuri 
were noted•
On 20.10.54 however the patient complained of a very 
itchy/
itchy skin, and that she could not sleep at night for 
the itch. The onset was quite sudden. Examination 
revealed a generalised patchy eruption of the trunk 
and legs, the rash was slightly raised, and in appear­
ance resembled an urticaria. An injection of 0.3 gm. 
Theostab. was given, and repeated a week later. At 
the end of this time the rash had disappeared and the 
patient felt very comfortable. When last seen at the 
Clinic on 3rd Nov. 1941 she was enjoying normal health.
SUMMARY OF CASE. The total amount of arsenic given
|
over a period of seven months amounted 
to 1.85 gms. Neoarsphenamine.
1.27 gms. Sulpharsphenamine.
There were unmistakable early signs of intolerance to 
arsenical therapy, before the onset of purpuric haemor­
rhages .
A comparatively small total amount of arsenic was ad-
I
ministered and small doses were given during the second
j
and last series of arsenical injections. j
ii
The patient was suffering from a discharging ear, and I
i
the tonsils were unhealthy at the time of the onset of 
symptoms•
The spleen was slightly enlarged.
The onset of symptoms occurred about twenty-four hours 
after the injection of arsenic.
Thrombocytopenia and anaemia were the outstanding 
features in the blood examination.
SJBQTIQK H I . 
DISCUSSIOK.
The Disease and its stage.
The Drug Employed, dosage, and duration 
of Treatment.
The type of Individual.
The onset of Symptoms.
Essential Features of the Blood Examination.
Suggestions as to the prevention of the 
Complication.
Treatment of the Established condition.
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(1) THE DISEASE AND ITS STAGE*. j
The incidence of syphilis is reckoned to be j
i
about 5 per cent in the general population, and the I
manifestations of syphilis are so protean that it 
might be argued that the syphilis per se was the cause 
of the purpura, j
j
Lovemann (1936) has drawn attention to the possi- | 
bility of syphilotoxic action on the bone marrow.
I have been unable to find any record of purpura 
haemorrhagica oocurring in an untreated case of 
syphilis.
Owing to the fact that Bismuth is frequently j
administered concurrently with the arsphenamine, it
i
might be argued that the Bismuth was an aetiological 
factor in the development of post-arsphenamine purpura,!
but a perusal of the literature yields no record of j
!
such an incident. ;
In one of the six cases now reported the blood 
Wassermann was negative, the diagnosis of syphilis having 
been established by the presence of the spirochaeta 
pallida at the site of the primary lesion.
t ;
In this case no generalised infection could have taken | 
place, and the vessel walls could not at this stage of I 
the disease have been subjected to the toxic influence \ 
of the infection, yet in this case purpura haemorrhagica 
occurred.
It/
It seems therefore reasonable to conclude that the;
i
stage of the disease itself does not play a significant 
part in the aetiology of this type of purpura*
Increased permeability of the vessel wall probably 
does exist and may be a contributory factor in the 
haemorrhage, but it is unlikely that the syphilitic
i
toxin is the cause of the increased permeability in \
!
the first instance* j
|
(2) THE DRUG EMPLOYED, ITS DOSAGE, AND THE DURATION
OP TREATMENT*
THE DKUG*
In all the six cases the particular brand of 
arsenic used was made by Burroughs Wellcome & Co. J
The Neoarsphenamine is known as "Neokharsivan", and thi
i
sulpharsphenamine as "Kharsulphan" • I
I
Prom Table V it will be observed that a com- j
j
bination of Neoarsphenamine and Sulpharsphenamine j
was used in four cases* In one case (No.2) Sulphars- j 
phenamine was the only drug used, and in another (Ho.4) 
Neoarsphenamine was used alone.
Comparing/
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Comparing these two cases we find that 7.95 gms. j
i
Sulpharsphenamine was administered over a period of
i
seven months, the average weekly dosage being 0.28 gm.,; 
whereas, 5.25 gm. Neoarsphenamine was given over a 
months. In the latter case the average weekly dose was 
roughly one gram greater than in the former. Assuming 
that the arsenic was responsible for the mishap, we 
might reasonably have expected the neoarsphenamine to 
cause the more severe reaction. Actually this was 
not so. Case No.2 died from extensive purpurichaemor- 
rhages, whilst No.4 made a rapid and spontaneous re­
covery, after comparatively slight purpuric symptoms.
In Case No.3, 6.75 gms. sulpharsphenamine was
given during a total series of twenty-four injections, 
whilst only 0.45 gms. neoarsphenamine was given during 
the same series of injections. When compared with the 
sulpharsphenamine, the amount of neoarsphenamine given 
in this case w&s so small that it might be entirely 
discounted. The average weekly dose of sulphars­
phenamine might therefore be reckoned to be 0.2 gm.
Grouping Cases one, five and six together the I 
total amounts of neoarsphenamine and sulpharsphenamine | 
given amounted to 8.8 gms. and 8.7 gms. respectively, j
S v I
Therefore no definite conclusion can be reached from 
these cases as to which drug is the more toxic or which 
one the more likely to cause purpuric symptoms.
A/
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A comparison of Cases 2 and 4 however suggests that
i
j
sulpharsphenamine is the more dangerous drug. Case i
« 1"O.g serves to show that comparatively small doses of
i  !
this drug are capable of producing purpuric symptoms.
DOSAGE.
In no case did the dose of the drug administered 
exceed 0.45 gms. The average weekly dose was much 
below this. Compared with*the usual doses given to j 
patients in the early syphilitic stage, the average 
weekly dose in these cases was comparatively small.
The average total amount of arsenic administered 
was correspondingly small. In a first unit course of 
three months the patient usually receives about 4.2 gms!
*. Ifc
arsenic.
In no case in the present series did any patient receive
i
more than 3.9 gms. of arsenic during a unit course.
In three out of the six cases reported the onset of 
symptoms appeared during, the third course of arsenical I
I
treatment•
In two cases, symptoms appeared during the second coursie 
and in one case symptoms did not appear until the fourt|h
Ii
course of injections.
It would seem that neither the particular dose nor
the total amount of arsenic administered can be re- !
|
garded as solely responsible for the onset of purpuric 
symptoms.
It/
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It will be observed from Table VI (column .V/) j 
that purpura can occur after a comparatively small dose! 
of arsenic. The patient (Oase Mo.5) received no i
arsenic over a period of one year* yet the administra­
tion of three doses, amounting in all to 0.375 gms. 
Sulpharsphenamine was followed by purpuric symptoms.
i
The period of time over which the patients were 
treated with both arsenic and bismuth varied consider­
ably. (Table VI).
I
The longest period was twenty-seven months (Oase 
5) and the shortest period 4$ months (Case 4).
i
The average duration of combined treatment was | 
15£ months•
Regarding treatment with arsenic alone, the averagje 
length of treatment was seven months.
The relationship between the duration of treatment! 
and the mode of onset of symptoms is worthy of comment.!
j
It will be seen from Table VI (column 6) that there
j ■
is a tendency for symptoms to appear more suddenly in ||
those cases longest under arsenical treatment. |
I
f
The actual duration of the treatment however does !
i
not seem to be a factor in the causation of the com- j 
plication. |
Reference might be conveniently made at this point
79.
to the relationship existing between the duration of 
treatment and the number of platelets.
An interesting comparison can be made, if these 
six cases are studied in two groups.
Group I comprises the cases treated over the
longest period of time, (1, 3, 5). !
!
Group II, those cases where treatment was of I
Ii
shorter duration, (2, 4, 6).
In Group I the average platelet count at the 
onset of symptoms was 352,000 per o.mm.
In Group II the average platelet count was 
27,000 per o.mm.
It would therefore appear that the duration of 
treatment with arsenic has no effect upon the number of 
platelets in the circulation.
(3) TYPE OK INDIVIDUAL AND 3TATE OF HEALTH AT THE----- time" “op oir&EroF fw&mr. —
Five of the six cases now reported were females.
i
I
The average age was thirty-eight. j
With one exception the Blood Wassermann was 
positive, and the stage of generalised syphilis had j
been reached in all five cases. In no case was there |
j
any familial tendency to bleeding, and there was no j
i
haemorrhagic tendency in any of these patients.
There was no history of serious chronic ill-health
in/
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in any of the six patients* and they all appeared to 
enjoy normal health.
When the symptoms of purpura occurred* there was 
one outstanding pathological feature present in all 
the six patients• This was the presence of a septic 
focus of infection* the seat of the focus was in the 
mouth* or in the tonsils in five of these oases.
In the one exception the seat of infection was in the 
ear.
Toxic Factors summarised.
' ii
Case I. The tonsils and gum margins were in a septic 
condition when purpuric symptoms occurred. | 
The presence of non-haemolytio streptococci 
and staphylococcus (albus) was demonstrated 
in culture.
Case II. There was a histofy of frequent sore throat,
I
the tonsils were enlarged and pus was 
present in both tonsils.
Case III. The patient suffered from sore throat for 
ten days prior to the onset of purpuric 
symptoms. The tonsils were enlarged and 
septic.
On culture haemolytic and non-haemolytic 
streptococci, staphylococcus albus and 
coliform bacilli were isolated from the 
tonsillar region.
Case' IV./
81.
i
| Case IV. The right tonsil and the lower teeth were !
source of toxic infection, a culture from |
I i
the lower gums showed the presence of non- j
I i
haemolytic streptococci, and diphtheroid
j
bacilli. A culture from the tonsil yielded j
a growth of non-haemolytic streptococci and i
staphylococcus albus.
I ' j
! Case V . The patient suffered from occasional sore j
j i
; throats before the commencement of anti- !
syphilitic treatment. I
! • ■ it
The teeth had been extracted three years |
previously because of pyorrhoea. j
The tonsils were in a septic state and a j
; I
culture showed the presence of non-haemolytip 
streptococci. j
1 • I
: J
| Case VI. The patient complained of a discharging ear, j
I when she received her final injection of
arsenic. The discharge had existed for
j i
! fourteen days• There was no history of ear !
; I: |
trouble prior to this time. On culture, a j
;
growth of staphylococcus albus, and coliform 
bacilli was obtained from the ear-. The 
throat was congested and this yielded a 
profuse growth of streptococci viridans and 
staphylococcus albus. I
It/
It is obvious that in all these sd-x oases, there 
existed, a state of* chronic sepsis.
It is submitted that there exists a distinct re­
lationship between these septic foci and the clinical 
picture of purpura haemorrhagica following the ad­
ministration of arsenic.
Hitherto much importance has been attached to the j 
presence or absence of thrombocytopenia. In nearly allj 
the cases reported in literature of purpura haemor- i 
rhagica following arsenical treatment, the report is j 
accompanied by the findings in the blood count, and I 
the blood platelet count.
In these cases thrombocytopenia was almost in­
variably present, and stress has been laid upon this 
finding. But thrombocytopenia, per se, does not 
explain the occurrence of purpura - nor does it give 
us any conception of the pathogenesis underlying the 
condition.
MacKay (1931) found that in cases in which toxaemia
i
existed, a reduction in the number of platelets fre- \ 
quently occurred. It may well be that the arsenic in ! 
the arsphenamines in the first instance, damages the j 
capillary endothelium and a superimposed toxaemia causes 
a reduction in the circulating platelets, so that the I 
damaged capillary walls then lack the protection of th^ 
platelets. If this i3 so, it would seem that the term 
thrombocytopenic purpura, as applied at present to
purpura/
purpura haemorrhagica following arsenical therapy, 
although of clinical and histological interest, has 
no pathological meaning. The essential feature is not 
the presence of thrombocytopenia, but the existence of 
some toxic factor which first causes thrombocytopenia. 
The all important factor would then be the degree of 
toxic infection. The more severe the toxaemia, the 
more marked will be the thrombocytopenia, and accord­
ingly the more prolonged and severe will be the haemor­
rhage owing to lack of platelet protection to the 
vessel wall.
(4) THE 0M3ET OF SYMPTOMS.
Purpura haemorrhagica, in the course of arsen- i 
ical treatment is a complication of sudden and dramatic
I
onset. It usually occurs within a comparatively short I
i
time after an injection of arsenic. The onset howeverj
is seldom immediate, although such a case has been !
I
reported upon by S. Morton Smith. Generally, however j 
there is a lapse of time, varying from a few hours to 
as many days, between the injection and the onset of 
symptoms. P.O. Combes (1927) reports on a case in j 
which/
which this interval extended to twenty-one days, and 
E.T. Burke (1941) reports an interval of fifty-eight 
days in one of his cases.
In the series of six cases now reported two days 
was the longest interval to elapse, and two hours the 
shortest. The average intervals was 14§ hours. j
In the cases taken from literature, omitting the j
| !
two reported by Combes and Burke, these being quite
i
exceptional in this respect, the average interval be- | 
tween the administration of drug and the onset of 
I symptoms was four days. !
It is impossible in the early stages to forecast jI
with any degree of accuracy the prognosis of the case. i
i
Patients with comparatively mild early symptoms can j 
rapidly become critically ill within a few hours of the
j
onset of haemorrhage. There i3 very little clinical j 
indication at the onset of the serious nature of the j 
complication. Case No.2 in the present series serves < 
to illustrate this point. The patient reported to i
i
hospital with purpuric haemorrhages on the buttocks and 
legs. Apart from thi3 she was feeling well, with no I 
other outward manifestation of her critical condition.!
i
j
Th© following day she became extremely ill, with j
extensive haemorrhage accompanied by shock. It happens 
not infrequently that the patient complains only of a j 
few haemorrhagic spots or bruises and it appears 
impossible/
impossible to assess how much damage has been in­
flicted on the vascular and haemopoietic systems.
It is thus essential to investigate thoroughly such 
prodromal symptoms as may occur. These may be slight 
and fleeting, but nevertheless they afford timely and 
certain warning of impending disaster.
The important and most frequent premonitory sym­
ptoms include:-
(1 Shivering (generally a few hours after an 
injection of arsenic).
(2) Malaise (within twenty -four hours).
(3) Sickness (immediate).
(4) Dizziness (immediate).
(5) Fainting (immediate).
(6) Vomiting (immediate).
(7) Skin rash, or patchy dermatitis. f
(8) Headache (some hours).
(9) Vaso-dilator reactions (immediate).
Once established, the complication is characterised 
by haemorrhage, in one form or another. This usually j 
takes the form of petechial haemorrhages into the skin,!
purpuric spots or ecchymosi3. Bleeding frequently j
i
takes plaee from one or other of the mucous surfaces, j
i
it may occur in the viscera and from the serous surfacejs. 
External haemorrhage most frequently takes place from 
the nose and from the gums•
Melaena and haematuria may occur if the complica­
tion/
complication assumes a severe degree* This occiirred 
in Case Ho*2 of the present series, and it will be noted 
that this is the only case where there was complete 
absence of platelets.
The areas from which haemorrhage occurred in the 
six cases now reported are tabulated below.
TABLE VII.
Case
Ho. Skin.
&ums and Mucous 
Mem. of Nose 
and Throat. Internal•
1 Hr* 0
2 0
3 + 0 0
4 + ++ 0
5 0 0
6 + 0 0
0 = Mil. + = slight ++ = moderate. +++ s Severe
Haemorrhage into the skin was present in all the six 
cases. A moderate amount of haemorrhage from the gums 
and mucous membrane of the nose and throat occurred in 
two cases, and internal haemorrhage was severe In one 
case, which proved fatal.
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iI
j
(5) ESSENTIAL FEATUKES IN BLOOD EXAMINATION #
The blood findings in the six oases reported j
!
are given in Table VI. j
■ j
Case 1. A moderate thrombocytopenia was present.
Haemorrhage was not extensive or severe.
There was no other abnormality found. j
l
Case 8 . The blood showed the presence of a very marked 
anaemia with great reduction of red cells. 
Leucopenia and granulocytopenia were marked 
features.
There was a complete absence of blood platelets. 
Haemorrhage was extensive and severe* The i
bleeding time was prolonged. The capillary 
resistance test was positive.
Although the patient was given five trans­
fusions, she died nine days after the onset 
of symptoms.
Case 5 . With the exception of a moderate degree of
anaemia this patient presented a perfectly j
i
normal blood picture. Haemorrhage was not j
i
severe.
i
Case 4. A moderate degree of anaemia was present.
The essential features were the presence of 
a leucocytosi3 and a severe thrombocytopenia.
The bleeding time was definitely increased. 
Haemorrhage was moderately severe.
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Case 5
Case 6i — i— —
Anaemia was present. The white cell oount 
showed a leuoooytosis, and the differential
I
oount a marked granulocytopenia. The platelet 
count was 556,000.
Haemorrhagic symptoms were not severe. The 
patient had not observed any frank haemorrhage*. 
The patient did not report to hospital until j 
seven days after the onset of his symptoms, j
I
and it i3 probable that after this interval ! 
of time the blood platelets would be restored j
to their normal numbers. j
Iii
Moderate Thrombocytopenia was the only featur^
j
presentj although there was extensive haemor­
rhage into the skin, there was no bleeding 
from the mucous surfaces.
(See TABLE VIII)
TABLE
Poly- Lympho- Sosino-
Case Hb. Red White Morphs cytes phils.
No. 0®lls Calls % %
1 68 3,680,000 5,800 78 20 1
2 27 1,590,000 3,600 30 65 3
3 60 4,500,000 8,740 72 25 . . 1
4 62 3,410,000 12,400 75 25 2
5 56 3,010,000 13,500 28 66 2
6 65 3,000,000 4,200 68 30 1
Reticulo- Blaedipg Caagul.
cytes. plate— Time Time. Capillary
% lets. Mins. Mins Resistance. Result.
1 200,000 4 5J- Positive Recovered
2 Nil 15 7-J- Positive Died
•9 300,000 3 4 Neg. Recovered
•9 25,000 12 4j Positive Recovered
1 556,000 4^ 3j- Neg. Recovered
0*5 56,000 5 3J- Neg. Recovered
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A study of the blood findings summarised in Table j 
VIII indicate that:- !
i
(1) Purpura haemorrhagics following arsenobenzol therapy 
can occur in the presence of a normal blood picture*
(S) In all cases of post-arsphenamine purpura there 
tends to be an anaemia of the secondary type*
This anaemia is in no way distinctive*
(3) The severity of the haemorrhage appears to depend 
upon the degree of thrombocytopenia present.
(4) The bleeding time varies inversely as the number
of circulating platelets. I
(5) A negative capillary resistance test does not 
necessarily indicate the absence of purpura haemor* 
rhagica. The test may be negative in the presence 
of purpuric symptoms. i
(6) Periodic enumeration of the blood platelets during; 
treatment with arsenic is of distinct value, as
it may yield a clue to the patient*s susceptibility 
to purpura.
(7) A study of the blood picture, made directly after
i
the onset of purpuric symptoms i3 of great prog­
nostic value. ij
Leucopenia, and an accompanying low polymorpho- \
i
I
nuclear count are unfavourable indications. j
j
(8) The presence of a neutrophil leucocytosis may be j
regarded as a favourable prognostic sign. ;
(9)/
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(9) If thrombocytopenia exists itself, without de­
pression of the white cell elements of the blood 
the patient will probably make a spontaneous 
recovery. A persistent and severe thrombocytopenia 
is of serious import.
(6) SUGGESTIONS AS TO THE PREVENTION OF THE 
IMPLICATION. -------------------------
(1) Before treatment is commenced a thorough search !
J
should be made for the presence of any toxic focud 
of infection. If such a focus be discovered no 
arsenical treatment should be administered until 
the source of infection has been completely 
eradicated. In all the six cases reported a toxic 
focus was present.
(2) A patient undergoing arsenical therapy should be 
thoroughly interrogated at each attendance as to j 
any effect felt after any previous injection of 
arsenic. Prodromal symptoms were found in four i
of the six cases now reported. j
i
Of the thirty-six cases reported upon from litera4 
ture twenty-two of these experienced prodromal 
symptoms•
Should a history of some untoward reaction be 
elecited, the patient should not be given a further 
injection of arsenic, until such reaction can be 
satisfactorily proved not to have been due to 
arsenical intolerance.
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(3) A complete blood examination should be performed 
before beginning treatment with arsphenamine.
Where there is marked anaemia (below 60 per cent
!
Haemoglobin), or an obvious diminution in the red 
or white cell count, treatment should be withheld.
(4) Every patient undergoing arsenical treatment should 
have a blood examination done periodically. The 
presence of thrombocytopenia indicates that a 
destruction of platelets is taking place.
If thrombocytopenia is present, a daily estimation 
of the platelets should be made• I
A mild leucocytosis may indicate the presence of 
a toxic factor.
(5) A patient showing a marked thrombocytopenia (below 
200,000, or a decrease in the number of polymorpho­
nuclear cell3 should be hospitalised.
(6) The substitution of mapharsan (obtained by the
oxidation of arsphenamine) in place of the arsphen- 
amines appears worthy of trial. Falconer and 
Epstein (1936) report favourably upon the former j 
drug. Five cases who exhibited symptoms of i
purpura after the arsphenamines, were tested for 
sensitivity to mapharsan. In no instance was 
there any constitutional reaction, or any untoward 
reaction after mapharsan. j
17)/
Since the introduction of arsphenamine in the 
treatment of syphilis various workers have attemp­
ted to reduce the toxicity of the drug, and thus 
lower the incidence of such reactions as post- j 
arsphenamine purpura.
The method adopted has been to add to the solution 
of the arsenic, or to administer concurrently,
some substance which would be thought an improve- !
|
ment on the arsenic itself.
The substance perhaps most frequently used in thisj 
way has been glucose, and many workers have claime^ 
that it reduces the toxicity of the arsphenamine. ; 
Calcium in the form of calcium gluconate, and j 
sodium thiosulphate have also been widely recom­
mended for use with arsenic.
Doak (1941), who has made an extensive survey of 
the literature apppertaining to this particular 
aspect of arsphenamine therapy comes to the con­
clusion that, so far the clinical results are in- j 
conclusive, and that in spite of the many combina­
tions that have been suggested none have been con-j 
clusively shown to have any advantage over ars- j 
phenamine solutions alone•
(7) TREATMENT OF THE ESTABLISHED CONDITION.
Any discussion of the treatment of post-arsphenami)ne 
purpura must take into consideration the fact that a
large number of cases recover spontaneously. Five of !
!
the six cases now reported fall into this group. |
|
In the absence of any certain understanding of the
l
aetiology of this form of complication, treatment must jiI
be more or less empirical. It is therefore expedientj 
to adopt any line of treatment that might reasonably b0 
expected to afford relief of symptoms.
As a result of haemorrhage, the patient may lose, 
in a comparatively short time, a considerable amount off 
blood. In this form of purpura the initial bleeding 
may be slight but it is impossible to judge clinically 
to what extent further haemorrhage may take place 
within a very few hours.
Depending upon the extent of haemorrhage the 
patient may suffer from shock, this, along with our 
uncertain knowledge as to how serious the reaction 
may become, is sufficient justification for the immed­
iate hospitalisation of the patient.
It i3 essential that a blood count should be done 
in order to assess:
(1) the extent of anaemia present.
(2) the degree of thrombocytopenia, if any
and (3) the extent to which the bone marrow is
affected, if at all.
The most serious symptom is the presence of haemorrhage* 
The extent of bleeding may vary from a few petechial spots 
to very extensive haemorrhage from the mucous membranesj, 
and viscera* An alarming feature of post-arsphenamine ! 
purpura haemorrhagica is the uncertain nature of its 
pathology, and the unknown extent to which haemorrhage ; 
may take place* Therefore in every case, no matter 
how slight, the first essential is to endeavour to |
i
avert such haemorrhage as may exist, and to combat 
anaemia. A variety of therapeutic agents have been 
used, all with this object in view, and opinions differ 
widely as to their value.
i
Transfusion in post-arsphenamine purpura.
Case No.2 of the present series was trans­
fused five times with one pint of blood.
The patient received her first transfusion the day 
after she was admitted to hospital, and as soon as it 
was seen that the haemorrhage was likely to be extensive. 
In this case the blood picture denoted severe damage to 
the haematopoietic system, and this was present when 
the patient came into hospital, i.e. three days after 
the onset of symptoms. Had this patient reported to j
hospital at the onset of her first symptoms transfusior^ 
might have saved her. j
In one case reported by Moore and Keidel (1921) the I
patient/
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patient was first transfused eleven days after the onse 
of symptoms. This patient was transfused with 250 oo. 
oitrated blood on four occasions. As a result of this 
there was a marked increase in the haemoglobin and red 
cells, but nevertheless the patient died four weeks 
from the onset of symptoms.
Dodd and Wilkinson (1928) reviewed twenty-four cases of 
severe granulocytic aplasia of the bone marrow after I 
arsphenamine treatment. Twenty of these showed signs 
of purpura. Transfusion Therapy was tried in six cases 
of purpura, but in no case was there any improvement• 
Peck, Kosenthal and Erf (1936) report on two cases of 
acute purpura haemorrhagica. In spite of many blood 
transfusions, both patients died.
Jones and Trocantins (1936) report on twenty-two cases 
of purpura haemorrhagica, all of which were treated with 
blood transfusion. In eight cases the treatment was 
entirely successful. In seven cases the result was 
only temporarily beneficial, and in seven cases the 
transfusion failed to have any effect on the course of 
the disease. These authors conclude that "contrary to 
their former opinion* transfusion treatment is not 
always effective even when given under the best con- ;
i
ditions. I
The present position may be summarised by saying
j
that although blood transfusion has been found to 
benefit the anaemic condition of the patient in cases 
of/
of purpura, the bulk of evidence appears to show that 
no constant or beneficial effect can be confidently 
anticipated ae a result of blood transfusion in cases 
of post-arsphenamine purpura.
Platelet Response to X-Ray Therapy. Mettier and Stone 
(1936) report on six case3 of thrombocytopenic purpura 
treated with X-Kay to the spleen and one with X-Hay 
over the long bones. The dose was 200 to 300 units 
given daily for six to fifteen days. These authors 
state that prior to treatment the platelet count varied 
from 10,000 percmm. to 40,000 per c.mm. Six of these 
patients showed an increase in platelets beginning 
within twenty-four to forty-eight hours, the platelet 
oount reaching between 250,000 per c.mm. and 500,000 
per c.mm. in nine days.
Davidson (1936-1937) submitted three cases suffering 
from thrombocytopenic purpura to X-Kay treatment, the 
dosage being that suggested by Mettier and Stone (1936)j 
Mo significant change however was noted in the platelet 
count in any of the three cases.
j
Further investigation of this form of treatment is 
necessary before any conclusion can be reached regard­
ing its efficacy.
Liver. Jacob and Clapperton (1930) claim to have cured 
one patient suffering from throbocytopenic 
purpura with liver extract after failure to obtain/
obtain satisfactory results with collosal calcium and |
haemoplastin. I
Box and Massingham (1931) report upon the effect of |
liver therapy used in one case of purpura haemorrhagida 
complicating Scarlet Fever. These authors claim that 
liver causes a rapid and progressive increase in the 
number of blood platelets, and in the case treated 
there was an obvious improvement in the haemorrhagic 
symptoms within twelve hours. j
I
Witts, J.L. (1931) reports in five cases of thrombo­
cytopenic purpura treated with liver. Hone of these j
i
cases derived any benefit from the treatment. In no
i
case was there any permanent increase in the number of ! 
platelets, and all the patients continued to bleed
during the liver treatment. !
I
In my own series of cases, liver therapy was used in 
one patient. The liver was given at the same time as | 
the blood transfusion. The patient received 5 cc. j
Pernaemon Forte on four occasions over a six day period*
]I
The patient continued to bleed freely, there was no 
improvement in her symptoms, she finally became comatose 
and died five days after the institution of liver j
therapy• j
Such evidence as at present exists appears to support j
i
the view that liver therapy has no power to diminish j
I
the haemorrhage, or to increase the platelets in 
thrombocytopenic purpura.
Parathyroid Gland. Lowenburg and Ginsburg (1932)
report the result of their observa-j
i
tions after parathyroid extract hadl 
been administered in two cases of thrombocytopenic 
purpura.
In one case it was noted that on the second day of 
parathyroid administration, the bleeding time fell from 
over two hours (noted on admission) to between five and 
six minutes, and all visible haemorrhage had ceased. \ 
In the second case, (after over a month’s treatment 
with moccasin snake venom, without clinical improvement) 
parathyroid extract was administered. Following this
treatment clinical improvement was noted and the bleedH
i
ing time was markedly decreased.
These authors claim that after hypercalcaemia was I
established there was a rise in the blood platelets 
and clinical cure followed in both cases. !
Mathewson and Cameron (1937) treated one case of idio­
pathic purpura haemorrhagica with intramuscular in- j 
Section of parathormone (Lilly). This treatment pro- j 
duced practically no effect on the blood serum calcium,| 
nor was there any rise in the blood platelets. I
This form of treatment has not had sufficient clinical I 
trial to permit any definite conclusions being formed. |
Snake Venom. Peck and Ebsenthal (1935) suggest that
the venom of the Moccasin snake, used in 
solution of 1 in 3000 in physiological
saline/
saline is of value in the treatment of purpura haemor-
|
rhagioa. The initial injection in patients over ten j 
years is 0.4 c.cm. subcutaneously, increased to 1 cc. j
i
as a maximum dose. This is usually given twice weekly»
and if symptoms are severe every third day.
Mine cases of purpura haemorrhagica with typical and
■
marked symptoms were treated with snake venom. j
The majority of patients showed a definite response to j
the treatment. Three other cases of purpura haemor- j
!
rhagica were similarly treated, but in these the venom 
was ineffective in checking the haemorrhage.
These authors conclude that snake venom diminishes 
the bleeding in certain cases of purpura haemorrhagica, 
but it in no way affects the blood picture.
Greenwald (1935) has U3ed this venom in three cases 
suffering from purpura,with satisfactory results. The i 
results showed that actual bleeding stopped in all three 
patients after the third or fourth injection. The 
cardinal signs of thrombocytopenic purpura were present 
in each case at the first examination. After the in- j  
jections of snake venom the bleeding time became normal 
in all the three cases.
In two patients the capillary resistance test which was 
strongly positive at the first examination, became 
negative after two months.
Peck, Rosenthal and Erf (1936) studied the effect of 
subcutaneous injections of Moccasin snake venom in 
thirty-two/
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thirty-two oases of chronic purpura haemorrhagica.
These authors claim symptomatic improvement in seventeen 
of their cases, four cases failed to show any response, 
and eleven cases required either splenectomy or ligatiojn
of the splenic artery.
Davidson (1936-1937) endeavoured to obtain successful 
results in three cases of thrombocytopenic purpura with 
bi-weekly injections of snake venom given according to 
the instructions published by Rosenthal. In no case 
was there any improvement noted.
Lowenburg and Ginsburg (1936) failed to obtain any 
success in a case of thrombocytopenic purpura treated 
with mocassin snake venom for over a month
A final conclusion cannot at present be reached 
regarding the efficiency of snake venom as a therapeuti|c 
agent in post-arsphenamine purpura. There seems to be 
a considerable diversity of opinion among competent 
observers as to the efficacy of this form of treatment 
and critical evaluation of the results is difficult.
Calcium. In case Mo.5 of the present series, the
patient received fifteen bi-weekly injections 
of 1 cc. Colloidal Calcium. Seven days 
after the final injection of calcium, arsenical treat­
ment was started. The patient had received only three | 
small doses of sulpharsphenamine before purpuric symp­
toms developed•
The/
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The inference is that calcium is not effective in pre­
venting the onset of purpuric symptoms.
Gorrie (1940) reports no success with calcium gluoonat€» 
given intramuscularly.
Vitamin C . Miller and Rhoades (1936) have studied the 
therapeutic effects of Vitamin C in a group 
of patients suffering from thrombocytopenic 
purpura. In four cases a persistent rise in the number’ 
of thrombocytes and complete relief from symptoms
followed the administration of ascorbic acid. In two
.
instances the clinical improvement was associated with 
an increased urinary output of ascorbic acid.
Davidson (1936-1937) on the other hand failed to obtair. 
a satisfactory result in any of these cases of thrombo­
cytopenic purpura which he treated with ascorbic acid. 
Witts (1937) reports no success in three cases of 
thrombocytopenic purpura after treatment with vitamin 
C.
Vaughan (1937) treated one case of thrombocytopenic 
purpura with ascorbic acid, but failed to produce any 
beneficial effect.
Wright and Lilienfeld (1936) studied the effect of 
the administration of crystalline vitamin C, in two 
cases of thrombocytopenic purpura haemorrhagicat 
although large doses of cevitannic acid was given, 
there was no evidence of a favourable effect in the 
clinical/
clinical course of the illness.
Scarborough (1942) states that he has recently treated 
seven cases of thrombocytopenic purpura with massive 
doses of ascorbic acid, without any demonstable effect j 
on either the blood platelets, the bleeding time or 
the capillary resistance.
Vitamin C has therefore had an extensive trial in the 
treatment of thrombocytopenic purpura. The majority 
of observers have failed to find any clinical benefit 
resulting from its use in this form of purpura, and it j 
does not appear probable that the administration of j 
jVitamin C would be of value in the treatment of post- 
arsphenamine purpura. j
i
Vitamin P . Scarborough and Stewart (1938) investigated] 
the therapeutic effect of Vitamin P in six ;
i
cases, all suffering from a deficiency of 
one or more vitamins in the diet. In three of these 
cases, spontaneous haemorrhages were present when they I 
first came under observation and all three were being |
j
treated with arsenic or bismuth for syphilis. j
Hesperidin (Vitamin P. Glaxo) was administered orally |
l
in doses of 1 gramme per day.
!
As a result of their investigations, these authors j
j
believe that Vitamin P can reduce the number of haemorH
!
rhages in patients who suffer from a vitamin deficiency*. 
Gorrie/ !
Gorrie (1940) reports favourably upon the use of 
Vitamin P in his case of purpura haemorrhagica after 
arsenioal treatment* This vitamin was administered by 
the mouth in doses of 0*25 gms. at two hourly intervals* 
After a total of 5.75 gms. no further bleeding was 
noted.
Scarborough (1948) believes that a deficiency of i
Vitamin P may produce a clinical syndrome in some way
|
analogous to purpura haemorrhagica, the salient features 
being petechial bleeding, a slightly prolonged bleeding 
time, and a low capillary resistance.
Before the administration of Vitamin P can have a 
rational basis in the treatment of purpura haemorrhagiba 
following arsenical therapy, it would first of all have 
to be established that increased capillary fragility ; 
is a constant and important faotor in the aetiology of j 
the condition.
j
If a decrease in the number of blood platelets leads 
to an increase in the bleeding time and also to haemor-j 
rhage, it follows that treatment should be directed j 
towards increasing the number of platelets.
Schiff and Hirschberger (1957) claimed to have increased
i
the number of platelets in normal and thrombocytopenic j
I
children by the administration of a fat soluble factor j
which they have designated for the time being, the j
i
•T* factor. This factor was found to be active in 
sesame/
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sesame oil eight to ten drops of which produced a 
notable rise in the platelet count.
I have been unable to find any further reference to or 
confirmation of this work. . i
It would appear that the various forms of treatment 
enumerated have been effective at one time or another 
in cases of thrombocytopenic purpura, and it would seeni 
reasonable to apply such treatment in oases of post- 
arsphenamine purpura. But it must be admitted that 
until now, no method or substance has been found 
uniformly benefioial in these cases. ;
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SECTION IV. 
CONCLUSIONS.
Post-arsphenamine purpura is an acute complication 
which may occur in any patient undergoing anti- 
syphilitic treatment. It may occur at any stage 
in the disease. It is however more likely to 
develop after a series of arsenical injections 
have been given, rather than in the early stages 
of treatment.
A complete study of the blood picture is necessary 
before the nature of the complication can be 
identified.
From a general survey of literature, and a partic­
ular study of the six cases in the present series, 
there seems a probability that the arsphenamines 
are capable of exerting damage on the capillary 
endothelium, but this does not appear to be the only 
factor of aetiological importance in post- 
arsphenamine purpura.
Neither the amount of the drug, the individual 
dose, or the duration of arsenical treatment are 
factors of aetiological importance. <
A study of the six cases reported suggests that 
the longer the duration of treatment with arsenic, 
the more sudden is the onset of the purpuric
symptoms.
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(6) The onset of post-arsphenamine purpura cannot be 
anticipated clinically. In the majority of oases 
it occurs within thirty hours after the arsenical
j : .
j  injection, although in exceptional cases it may be
delayed•
j (7) The early clinical signs in post-arsphenamine
purpura give no indication as to the future course 
of the reaction.
| (8) One sex is no more prone to the complication than
the other. The majority of cases occur between
the third and fourth decades of life. A probable 
explanation of this is that syphilis is relatively 
more common between the ages of thirty and forty, 
and the majority of patients undergo treatment
i during this period.
(9) In all the six cases now reported, a focus of
toxic infection was found present, and a state of 
chronic infection existed in these patients.
(10) Thrombocytopenia is not always present in post- 
arsphenamine purpura, and purpuric haemorrhages
i
may take place in its absence. Thrombocytopenia 
is not the responsible factor in post arsphenamine 
purpura, although the extent of haemorrhage may be 
determined by the degree of thrombocytopenia present.
(i d /
107
(11)
(12)
(13)
(14)
(15)/
It is suggested that the state of toxaemia whioh 
existed in these cases was primarily responsible 
for the occurrence of the complication* and that 
the thrombocytopenia was the result of a toxaemic 
condition.
Before arsphenamine treatment is instituted for 
syphilis, a thorough search should be made for 
the presence of any toxic focus of infection. j 
No arsenical treatment should be administered
I
before such a focus, if found, is completely | 
eradicated•
Prodromal symptoms are present in the majority of 
cases of post-arsphenamine purpura. Should a 
history of such symptoms be obtained, it is an 
indication that the administration of arsenic
!
should cease. i
is
Comparatively small doses of the arsphenamines I 
can produce purpuric symptoms, even after a pro- I 
longed period of rest from the drug. A patient j 
having once shown signs of post-arsphenamine j
purpura should not be subjected to further treat - j
j
ment with arsenic, until it is reasonably certain 
that no source of toxaemic infection exists.
j
108.
(16) Any patient who exhibits even the milder manifest:-
I
ations of purpura haemorrhagica after arsenical !
i
treatment should be immediately hospitalised* and!
i
a complete examination of the blood should be ;
made as early as possible.
' i
j
(16) Specific or standardised treatment of post- j
arsphenamine purpura has not yet been established!.
i
Blood Transfusion improves the anaemic condition 
of the patient, but does not arrest the haemor­
rhage, or in any way help to repair a damaged 
haematopoietic system.
X-Ray Therapy. i»iver Extract. Parathyroid 
Extract; Each of these agents have been used 
in cases of thrombocytopenic purpura.
The reports on the clinical results obtained 
are conflicting and no precise conclusion can 
be reached regarding their therapeutic value 
in post-arsphenamine purpura.
Calcium. The administration of calcium salts, I---------------------------------------------------------  I
either before or after the onset of purpuric |
i
symptoms has not given satisfactory results. !
Snake venon administered subcutaneously appears j
—  i - 1
to be of therapeutic value in checking the j
haemorrhage in some cases of purpura haemorrhagica,
i
but the results obtained with this agent have notj 
been uniformly successful.
Vitamins./
Vitamins C. and P. The value of vitamin C . in |
“ “ II
purpura haemorrhagica is at present open to doubt.; 
There is scant evidence on which to justify its 
use in post-arsphenamine purpura.
The administration of vitamin P appears to reduce 
the number of petechial haemorrhages in cases of 
post-arsphenamine purpura where an increased I
capillary fragility is associated with a vitamin 
P deficiency.
It is suggested that the incidence of post-arspheri- 
amine purpura could be greatly reduced, if efficient
I
prophylactic measures were adopted. This involve^:
j
(1) a thorough and systematic search for the 
presence of a toxic focus of infection in every 
patient undergoing arsphenamine treatment for 
syphilis•
(2) a careful inquiry as to the occurrence of any | 
untoward reaction following the injection of an j 
arsenical preparation.
i
(3) a complete examination of the blood, this 
being performed at frequent intervals during each 
course of arsenical treatment.
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